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Abstract 
Over the last two decades, hand, foot and mouth disease (HFMD) has become a major clinical 
problem in Vietnam and the Asia-Pacific region. HFMD affects children, especially those 
under 5 years old, and has pandemic potential. Since 1997, there have been several outbreaks 
with severe clinical phenotypes, including brain stem encephalitis, attacking millions of 
children and causing thousands of deaths. Synthesizing data on epidemiology, etiology, 
disease pathophysiology and economic burden of this emerging infection remains essential to 
inform clinical management and health policy makers in prioritizing the development of 
intervention strategies.  
Using data from >56,000 hospitalized cases over an 11 year period, I described the spatial and 
temporal distribution of HFMD in Ho Chi Minh City, the main hotspot of HFMD in Vietnam. 
I found that the disease started in the west and then moved to the south-east and finally came 
back the west of the city.  
Results from a prospective multi-hospital based study conducted during 2015–2018 showed 
that of ~1200 enrolled patients, enterovirus A71 (EV-A71) was the most common HFMD 
pathogen detected, while coxsackievirus A6 (CV-A6) has emerged and replaced CV-A16 to 
become the second most common virus causing HFMD in Vietnam during the study period. 
Despite the emergence of other pathogens and the diversity of enterovirus serotypes (~20 
serotypes) detected in HFMD patients, EV-A71 was the main cause of severe HFMD. Using 
long-term data synthesized as part of the research program, I also demonstrated for the first 
time that compared to EV-A71 subgenogroup B5, subgenogroup C4 was associated with 
more severe clinical phenotypes. Moreover, the predominance of subgenogroup C4 coincided 
with large, severe HFMD outbreaks in Vietnam (e.g. in 2011-12 and 2018). Collectively, the 
data suggest that an EV-A71 vaccine would be likely to substantially reduce the burden of 
HFMD, but a multivalent vaccine should be developed to control the ongoing HFMD 
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epidemic because CV-A6, CV-A10 and CV-A16 were responsible for approximately 12% of 
severe HFMD cases and cross-reaction between these CV-As and EV-A71 is poor.  
In order to improve our knowledge of HFMD pathophysiology, I used ECG signal recorded 
by a wearable device (e-Patch) to depict the distribution of heart rate variability (HRV) 
indices by severity and by detected pathogens and found that compared to mild disease HRV 
parameters reflecting parasympathetic nervous system activation in the severe group 
decreased whereas those mirroring sympathetic activity and autonomic nervous system 
imbalance increased. In a similar trend, compared to HFMD associated with non-EV-A71, 
HRV indices reflecting the imbalance between sympathetic and parasympathetic activation in 
HFMD associated with EV-A71 were significantly higher. This suggests that children with 
EV-A71 infection were more likely to have ANS imbalance. Alongside with these findings, 
the feasibility of this wearable device in children has brought promising applications in 
HFMD case management by early detection of severe disease in future.  
To inform health policy makers in Vietnam about the burden of HFMD, I also estimated its 
economic burden. I showed that the total cost per case for mild and severe disease was $245.8 
and $1326.7, respectively. Additionally, I also found that compared to CV-A infections, EV-
A71 infection resulted in higher illness costs. At nationwide level, the total economic burden 
in Vietnam was estimated at >US$90 million for two-year period of 2016 – 2017.  
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Chapter 1 
Introduction 
1.1. Epidemiology 
1.1.1 Case definition  
The term “hand, foot and mouth disease” (HFMD) was first used in 1959, in an 
article describing a cluster of cases centred around Birmingham (UK), 
characterized by fever, stomatitis and a vesicular rash.  The cases were detected 
after a pediatrician noted an unfamiliar cluster of these signs in a child and 
initiated  a referral to the specialist viral unit. When 3 other similarly affected 
children were identified, an alert was sent to general practitioners to report 
similar cases. Over the next 3 months, a further 82  patients with similar signs 
and symptoms were identified. The clinical features of the 24 cases which 
occurred in Birmingham, were described by Alsop et al [1]. The authors 
described presence of fever, mouth ulcers and skin lesions in 8%, 96% and 
92% of cases, respectively. They noted that these features were similar to those 
noted in an outbreak in Toronto (Canada) in 1957, and similar to the Toronto 
outbreak, coxsackievirus A16 was detected in one patient [2].  
Since then, HFMD has continued to occur throughout the world, notably 
causing large outbreaks particularly in the Asia-Pacific Region. Precise 
definitions of what constitutes HFMD have varied. According to some authors, 
an HFMD case is defined as any patient presenting with a typical rash (papular 
or vesicular rash) on hands, feet, mouth or buttocks with or without fever [3–5]. 
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In other words, the term “HFMD” includes the syndrome of herpangina (HA) 
and does not require the presence of fever. Others, however, have employed a 
case definition for HFMD which does include fever as well as the typical skin 
rash [6,7]. In 2011, the World Health Organization (WHO) proposed a 
definition of clinical HFMD of “febrile illness with papular/vesicular rash on 
palms and soles, with or without vesicles/ulcers in the mouth”. Similarly, they 
defined herpangina as fever, mouth ulcers and no skin rash [8].    
1.1.2 Historical outbreaks 
Following the report of HFMD in Birmingham, described above [1], other 
small outbreaks occurred in New York (USA), Sweden, Bulgaria and Hungary 
during the 1970’s. These comprised of 11, 195, 705 and 1550 cases, 
respectively [9]. Notably, the epidemic in Bulgaria had a high incidence of 
paralysis and killed 44 people, while the outbreak in Hungary was 
characterized by a mixture of aseptic meningitis, encephalitis and flaccid 
paralysis and caused 27 deaths in young children [9,10].  
Whilst in recent years, HFMD has been sporadically reported in European 
countries such as the UK, Norway, the Netherlands and Denmark [8,11,12], it 
has come to global renown due to outbreaks occurring in the Asia-Pacific 
region.  
Globally, outbreaks have totaled more than 16 million cases and 4 thousand 
deaths [4,6,8,13–18]. Most of these have occurred in the Asia-Pacific region 
[4,8].  
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Japan experienced two large outbreaks in 1973 and 1978, with a total of 39,597  
patients and a high proportion of patients with complications. Of the affected 
patients, 24% and 8% had central nervous system (CNS) involvement 
(localized encephalitis, aseptic meningitis and polio-like paresis), respectively 
[15]. In the 1980s, there were two notable outbreaks in Australia and Hong 
Kong. In Australia, a high proportion of cases presented with CNS 
involvement, and 51% (33/65) of hospitalized patients progressed to severe 
stages [8,16]. In 1985, 5 children in Hong Kong were reported to have HFMD 
and neurological complications. The next two decades witnessed many large 
outbreaks in Malaysia, Singapore, Japan, Taiwan, Vietnam and China [4,8,14]. 
The 1997 outbreak in Malaysia claimed lives of 29 young children and affected 
at least 2628 other patients [8,19]. One year later, Taiwan suffered from an 
unprecedented outbreak of HMFD, with an estimated 1.5 million cases, 405 
hospitalized young children with severe neurological complications and 78 
fatal cases [6,8,20]. In 2005, Tu et al described the first outbreak of HFMD in 
Vietnam through a study of 764 HFMD cases admitted to a referral pediatric 
hospital in Ho Chi Minh City [21]. Six years later, Vietnam experienced a 
large-scale outbreak with 113,121 cases and 170 deaths [3]. From 2008 to 
2014, several large HFMD outbreaks occurred in China, affecting 
approximately 11 million children and with a total of 3046 fatal cases [22]. In 
addition to these countries, HFMD was also observed in other countries, 
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including South Korea, Brunei, Thailand, Laos and Cambodia. In Cambodia, at 
least 54 children died in a 2012 outbreak of severe HFMD [8,14,23–25].   
1.1.3 Morbidity, mortality and patterns of distribution  
Formal reports detailing the prevalence, incidence or mortality rate of HFMD 
at national levels mostly come from Asian countries where HFMD is often a 
notifiable disease.  
In 1997, an estimated  7,253 HFMD cases and 40 deaths were recorded in two 
outbreaks occurring in Sarawak and Peninsular Malaysia [26,27]. Accordingly, 
the estimated incidence and mortality rate were around 33.6/100,000 and 
0.185/100,000, respectively (population of Malaysia in 1997 was around 
21,570,000). Between 1998 and 2005, a total of 2950 clinical cases and 10 fatal 
cases were reported to a sentinel surveillance program [27,28]. On average, the 
incidence rate was approximately 1.54/100,000 for each year in the period 
(average population of Malaysia for the 8 year-period was around 23,922,500) 
[29]. In following years, the number of reported HFMD cases was 210 in 2006, 
5380 in 2007, 450 in 2008, 381 in 2009 and 1647 in the first 33 weeks of year 
2010. Fatal cases from 2006 to 2010 were not documented. From 2011 
onwards, data on HFMD in Malaysia has not been formally published.   
In Taiwan, a study reported that there were a total of 1.5 million  cases and 78 
deaths among a population of approximately 21,178,000 in the 1998 outbreak, 
resulting an incidence rate of 609.6/100,000 and mortality rate of 
0.368/100,000 [20]. From 2000 to 2005, an analysis from the national sentinel 
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surveillance revealed that there were a total of 12,236 laboratory-confirmed 
cases, with annual average numbers of roughly between 1300 and 2500 cases 
[30]. Moreover, using the database of National Health Insurance, an 
investigation estimated that the yearly episodes of HFMD from 2006 to 2010 
were between 9823 and 133,461, with an annual incidence varying from 0.9% 
to 13.6% in children under 5 years old [31]. This study also provided the 
numbers of HFMD or herpangina for every 1000 emergency visits, with details 
in Figure 1.1. Regarding mortality, a total of 101 deaths were documented 
between 1999 and 2012, with the highest at 27 cases in 2001 [31].  
Figure 1.1: Proportion of HFMD or herpangina per 1,000 emergency visits 
in Taiwan from 2006 to 2014 [31]. 
 
In China, HFMD became a notifiable disease in May 2008. Data from China 
CDC revealed that the incidence rate of HFMD significantly increased from 
36.9 per 100,000 in 2008 to 161.6 per 100,000 in 2012. In addition, there was 
an upward trend in the mortality rate of HFMD in China between 2008 and 
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2012. The mortality rate remarkably increased from 0.01 in 2008 to 0.03 per 
100,000 in 2009 and reached a peak of 0.07 per 100,000 in 2010 before it 
leveled off at 0.04 per 100,000 in 2011 and 2012 [4]. From 2013 onwards, 
China reported hundreds of thousands of cases to WHO on a monthly basis, as 
shown in Figure 1.2 (WHO biweekly report).  
 
Figure 1.2: Distribution of HFMD by month in China [32]  
 
In Singapore, nationwide sentinel surveillance was officially established in 
April 1998. Since then, reporting of HFMD cases has become compulsory for 
all health care facilities and child-care centers. In 2000, Singapore experienced 
a large-scale outbreak of HFMD. The number of cases and deaths in this 
epidemic were 3790 and 3, respectively, making an incidence and mortality 
rate at approximately 94 per 100,000 and 0.074 per 100,000 [8], respectively 
(population of Singapore in 2000 was 4,027,900). For the next seven years, the 
incidence rates varied from 125.5 per 100,000 in 2001 to 435.9 per 100,000 in 
2007. From March to May 2008, Singapore witnessed another large outbreak. 
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The annual accumulative number of HMFD cases in 2008 was 29,686, 
producing an incidence rate of 613.5 per 100,000. From 2009 to 2017, average 
incidence rate was roughly 545 per 100,000. In terms of mortality, there were 
three cases reported in 2001 and one case reported in 2008. Besides these 
years, no deaths have been reported to the Ministry of Health in Singapore 
since 2001 [33,34].  
Table 1.1: Number of cases, population and incidence rate by year in 
Singapore [35] 
Year Number of cases Population Incidence rate  
(per 100,000) 
2009 17278 4,988,000 346.4 
 
2010 30878 5,077,000 608.2 
2011 20687 5,184,000 399.1 
2012 37125 5,312,000 698.9 
2013 31779 5,339,000 595.2 
2014 21797 5,470,000 398.5 
2015 28216 5,535,000 509.8 
2016 42154 5,607,000 751.8 
2017 33710 5,610,000 600.9 
2018 (first 19 
weeks) 
15505 5,783,000 268.1 
 
In Japan, the National Epidemiological Surveillance of Infectious Diseases 
(NESID) started in 1981. Since then, data on HFMD from thousands of sentinel 
sites have been reported to the NESID in accordance with the law. From 1982 
to 1997, a total of 1,294,638 HFMD cases were reported, with annual numbers 
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ranging from 21,000 in 1989 to 159,000 cases in 1995. For the next 12-year 
period, between 1999 and 2010, the average annual number of HFMD cases 
was 115,265, with the lowest and highest number of cases recorded in 1999 
(n=50,814) and 2000 (n=205,365), respectively. In addition, the annual 
reported herpangina cases ranged from 75,666 cases in 2009 to 154,802 cases 
in 1999. Totally, the incidence rates of HFMD and herpangina varied from 
112.69 per 100,000 in 2009 to 278.11 per 100,000 in 2000, with an average 
incidence rate of 189.76 per 100,000. Details are shown in Figure 1.3  [36].  
      
Figure 1.3: Distribution of HFMD/herpangina in Japan by years  
 
From 2013 onwards, data on HFMD was reported to WHO, with details being 
depicted in Figure 1.4 (WHO biweekly report). Generally, outbreaks of HFMD 
occurred every two years between 2013 and 2017 with the highest number of 
cases reported during weeks 27 and 33.       
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Figure 1.4 Distribution of HFMD by weeks between 2013 and 2018 in 
Japan [32] 
In Vietnam, the first case of HFMD was reported in 2003. Seven hundred and 
sixty four hospitalized cases were recorded in 2005. From 2005 onwards, the 
number of HFMD cases significantly increased to 5719 in 2007, then to 
157,391 cases in 2012. The incidence rate of HFMD in 2016 was noted at 
51.17 per 100,000 people [37].The number of HFMD cases and deaths are 
described in Table 1.2. Of note, Ho Chi Minh City has continually had the 
highest number of HFMD cases among 63 provinces of Vietnam (7816 cases in 
2014 and 5276 in 2015) [3,38]. 
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Table 1.2: Reported cases of HFMD in Vietnam between 2007 and 2017 
Year Number of reported cases Number of deaths 
2007 5719 23 
2008 10958 25 
2009 10632 23 
2011 113121 170 
2012 157391 45 
2013 79495 23 
2014 77296 9 
2015 56471 5 
2016 47428 2 
2017 46885 1 
 
1.1.4 Patterns of HFMD  
In Asian countries reporting HFMD, differing seasonal patterns have been 
noted in different countries or territories. For example, higher incidence 
between May and July in Japan, from February to May and September to 
October in Taiwan, between February and September in Malaysia, but year 
round (from January to December) in Singapore, Thailand and Hong Kong. 
China is a very large country, and different patterns were noted in different 
regions. For example, in Northeast China, HFMD was often observed from 
May to August while in the Southwest region HFMD mostly circulated 
between April and June [39].  
In southern Vietnam, according to a study of 764 children with HFMD 
admitted to Children’s Hospital 1, a large tertiary referral hospital for southern 
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Vietnam, there were two peaks of HFMD activity  during 2005. The first peak 
occurred between March and May and the second was observed from 
September to December [21]. Between 2006 and 2012, the HFMD pattern was 
not described in any formal publication, but a high number of HFMD 
admissions were recorded between February 2011 and July 2012 [40]. From 
2013 to the first 33 weeks of 2018, HFMD was mostly observed from 
September to November although it was reported throughout the year (Figure 
1.5) [38].   
 
Figure 1.5: Distribution of HFMD in Vietnam between 2013 and 2018 [38] 
1.1.5 Climatic factors and HFMD occurrence   
As I mentioned before, different distributions of HFMD have been observed in 
different parts of the world. The exact reasons for this remain unknown, but 
weather variation has been considered as a possible explanation. Dozens of 
studies focusing on association between climatic factors (e.g. rainfall, 
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humidity, sunshine hours, wind speed, precipitation and temperature) and 
HFMD incidence have been reported in recent years, with different statistical 
methods and inconsistent results (Table 1.2). In a systematic review published 
in 2016, Koh et al reported that mean temperature and absolute humidity 
positively correlated with HFMD incidence in Singapore and Tokyo whereas 
these correlations were not observed in Taiwan and Hong Kong. Moreover, the 
correlation between mean relative humidity with HFMD cases was only 
observed in Singapore. In addition to studies included in this review, several 
other studies from Japan, South Korea and China also show an association 
between ambient temperature, relative humidity and HFMD incidence. 
However, characteristics of this association were different among these studies. 
For example, the correlation phenotypes between HFMD incidence and 
temperature were both linear and non-linear. Moreover, the cut-off points of 
temperature and relative humidity were different, corresponding to distinctive 
weather of study settings [41–47]. Besides temperature and relative humidity, 
other climatic factors such as rainfall, precipitation, sunshine hours and wind 
speed were mentioned as the risk factors for HFMD in some studies. In 
Vietnam, there have been two studies reporting the effect of weather variables 
on HMFD incidence. The first study using daily cases from the sentinel 
surveillance in Can Tho – a city in Mekong Delta River region in the south of 
Vietnam revealed that the HFMD transmission was positively associated with 
temperature, humidity and rainfall. More specifically, HFMD incidence 
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increased 5.6, 1.7 and 0.5 percent for every unit increase of temperature, 
humidity and rainfall, respectively [43]. The other study utilizing data at 
nation-wide level for the period between 2011 and 2014, showed that at 
provincial level, the HFMD transmission in Vietnam was positively associated 
with humidity and temperature, but negatively associated with rainfall [43]. In 
summary, these two studies had consistent results in terms of the correlation 
between temperature, humidity and HFMD incidence, but inconsistent results 
with respect to rainfall. This may, in part, be due to the differing climates in 
Vietnam, with the southern region experiencing a tropical climate (wet and dry 
seasons) and the north more temperate (4 seasons). Moreover, this data from 
the studies, was of relatively short duration and included the large-scale 
outbreaks in 2011-2012 hence may not depict the whole story of HFMD in 
Vietnam. 
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Table 1.3: Climatic factors and HFMD occurrence 
Year Location Data Climatic 
variables 
Methods Key findings 
2012 
 
Fukuoka, 
Japan 
Weekly cases 
2000-2010 
Temperature (T)  
and humidity (H) 
Time-series 
analyses (TS) 
and distributed lag 
non-linear models 
(DLNLM) 
Average temperature (AT) and relative humidity 
(RH) associated with HFMD incidence. Every 1°C 
or 1% increase of AT or RH HFMD increases 11.2% 
or 4.7% respectively [41]. 
 
2017 
 
Japan Weekly cases 
2010-2015 
T, RH and total 
rainfall (RF) 
Maximum entropy 
method  
Mean temperature < 6
o
C or >30
0 
C was associated 
with growth in incidence rate [48] 
2016 
 
Korea Weekly cases 
2010-2013 
T, RH, sunshine 
hours (SH), 
precipitation (P), 
and wind speed 
(WS) 
Generalized 
additive model 
with smoothing 
splines 
HFMD incidence increased by growth of mean 
temperature and humidity [42]  
2017 
 
Can Tho, 
Vietnam 
Daily cases 
2012-2014 
T, RH, and RF  Generalized linear 
model  
A 1°C increase in AT was associated with 5.6% 
increase in HFMD rate. A 1% increase in H had 
equal influence of 1.7% increases on HFMD rate. 
An increase in 1 unit of RF was associated with a 
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0.5% increase of HFMD rate [43] 
2018 
 
 
Vietnam Monthly cases 
2011 - 2014 
T, RF and H Spatial 
autoregressive 
model  
 
RR increased by 3.1% for 1 °C increase in T above 
26 °C and 1% increase in H above 76% whereas 
HFMD decreased 3.1% associated with 1 mm 
increase in RF [49] 
2016 
 
Hong Kong 
China 
Daily cases 
2008-2011 
T, RH, WS, solar 
radiation (SR) 
and RF 
Negative binomial 
generalized 
additive models 
and DLNLM 
T and RH associated with HFMD incidence.  
Moderate RF and stronger wind and SR were 
associated with more admissions [50] 
2013 
 
 
Guangdong 
China 
Monthly cases 
2008 - 2011 
T, RH and SH  
 
Kulldorff scan 
statistic and spatial 
paneled model 
AT, RH, the proportion of population 5 years, male-
to-female ratio, and SH were the risk factors for 
HFMD [45] 
2014 
 
Mainland 
China 
Daily cases 
2008 - 2009 
T, RH,  
WS, P, 
atmospheric 
pressure and SH 
Logistic and auto-
logistic regression 
model 
Average P, AT, WS, the number of industrial 
enterprises above designated size, the population 
density and the proportion of student population 
were the risk factors for HFMD [46] 
2015 
 
 
Jiangsu 
China 
Monthly cases 
2009-2013 
No mentioned Space-time scan 
statistic and 
Bayesian model 
AT and RF were positively correlated with HFMD 
incidence, while the number of days with RF, low T, 
high T and SH were negatively related. Particularly, 
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RH had no relationship [51] 
2015 
 
Beijing 
China 
Individual 
cases 
2008-2011 
P and AT, RH 
and WS 
Geographically 
weighted 
regression model 
(AT had the greatest effect among the four weather 
factors. The influence of AT and WS speed were 
greater in the summer than the winter, the influence 
of P was positive in the summer and negative in the 
winter. RH was negatively correlated with HFMD 
[44] 
2015 
 
Suzhou 
China 
Daily cases 
2008-2013 
T, RH, RF, SH 
and WS  
 
Stepwise 
regression and TS 
AT and RF were strongly correlated with probable 
HFMD. Only EV-A71 cases were associated with 
AT during the study period of 2012–2013 [52] 
2016 
 
Mainland 
China 
Weekly cases 
2008-2013 
T, RH, RF, SH 
and WS  
 
The extra-Poisson 
multilevel spatial 
polynomial model 
T was highly associated with HFMD incidence. AT 
and T difference approximate inverse “V” shape and 
“V” shape relationships were associated with HFMD 
incidence. T can be used to explain most of variation 
of HFMD incidence [53] 
2016 
 
Qingdao 
China 
Weekly cases 
2007-2014 
T, P, 
RH and SH 
Descriptive 
statistical and 
correlation 
analysis 
Positively correlation between HFMD incidence and 
T, RH and P was observed [54] 
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2016 
 
China Monthly cases 
2008- 2012 
T, RH,  vapor 
pressure, 
atmospheric 
pressure (AP), 
RF, P, WS and 
SH  
Descriptive 
analysis, spatial 
statistic and  
spatial panel data 
models 
The effect of different meteorological factors 
including atmospheric pressure, vapor pressure, SH, 
T, WS, R and rain day count on HFMD incidence 
varied, depending on distinctive climatic zones 
across China [55] 
2016 
 
Guangdong 
China 
Daily data 
2009–2013 
T, RH, P, AP, 
WS and SH 
Mixed 
generalized 
additive models 
Significant non-linear positively effects of high RH 
were observed with a 13 % increase in the risk of 
HFMD. The effect geographically varied among the 
cities having different latitudes and longitudes [56] 
2017 
 
Beijing 
China 
Daily data 
2013 
AT, P, SH 
 
SaTScan analysis 
and spatial paneled 
model 
T, RH and WS were positively associated with the 
incidence rate, while P and SH had a negative 
association [57] 
2017 
 
Gansu 
China 
Individual data 
2010 
T, RH and RF Poisson regression 
model 
T was identified as a risk factor for HFMD. 
However, the cut-off point of T was not mentioned 
[58] 
2017 
 
Anhui 
China 
Daily cases 
2009-2014 
T, RH, RF, and 
AP 
 (DLNM) and 
SARIMA 
Relative risk for HFMD increased once AT was 
between 25 and 35
o
C or RH lied between 65 and 
80% [59] 
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2018 
 
Asia 22, 2017 for 
articles 
T and RH Systematic review 
and meta analysis 
Every one corresponding unit increase in T and RH 
were significantly associated with increased HFMD 
incidence. People living in subtropical and middle 
income areas had a higher risk for HFMD [60] 
2018 
 
Shanghai 
China 
Daily cases 
2009-2015 
T, RH, WS, RF 
and SH 
DLNM HFMD incidence increased alongside with 
increasing average RH and WS and with decreasing 
daily RF and SH [61] 
2016 
 
Hong 
Kong, 
Taiwan, 
Tokyo and 
Singapore 
Daily data 
1957-2014 
T, absolute H 
and RH 
Auto-regression 
model 
AT and absolute H positively statistically correlated 
with HFMD incidence in Singapore and Tokyo 
whereas these correlations were not observed in 
Taiwan and Hong Kong. The correlation between 
mean RH with HFMD cases was only observed in 
Singapore [39]   
2018 
 
Henna 
China 
Monthly data 
2012 -2013 
T, RH, WS, P, 
SH and air 
pressure 
GeoDetector and 
Bayesian space-
time hierarchy 
model 
1 °C rise in T was related to an increase of 4.09% in 
the HFMD incidence, a 1% increment in RH was 
associated with a 1.77% increase of the disease. 1% 
increment in ratio of urban to rural population was 
associated with a 0.16% increase of the disease [62]. 
2018 Beijing Daily data T,  Bayesian Mean temperature, relative humidity, wind velocity 
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 China 2010-2012 RH, atmospheric 
pressure, 
P, SH and WS 
conditional auto 
regressive 
(CAR) model 
approach 
and sunshine hours were all positively associated 
with HFMD. The effect of wind velocity was 
significant with a relative risk (RR) of 3.30 per 
meter per second increase, as was sunshine hours 
with a RR of 1.20 per 1 hour increase [63] 
2018 
 
 
Gansu 
China 
Weekly data 
2010-2014 
T , RH and RF Generalized linear 
regression models 
(GLM) and 
classification and 
regression trees 
(CART) 
Every 1 °C increase in AT was associated with a 
growth of 1.8%, 5.9% and 8% in HFMD incidence 
in Jiuquan, Tianshui and Lanzhou, respectively. 1% 
increase of RH could increase weekly HFMD of 
2.47% in Lanzhou and 1.11% in Tianshui. AT and 
RH were the first two important determinants of 
HFMD [64] 
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Guangdong
China 
Daily data 
2009-2012 
Air quality 
index (AQI) and 
T and RH 
DLNLM and 
TS  
Compared with low level T(≤23.5°C), high level T 
(>23.5 °C) had a RR of 1.486 on days with “good” 
air quality (AQI ≤ 46), and RR of 1.013 on days 
with “moderate” air quality (AQI>46). For RH, the 
high level (>77%) had a RR of 1.082 on days with 
“good” air quality, and RR of 1.039 on days with 
“moderate” air quality [65] 
20 
 
2019 
 
Henan, 
Anhui and 
Chongqing
China 
Bi-weekly data 
2008-2011 
T, RH, P and SH Dynamical 
stochastic SIR 
model 
Meteorological factors can not solely explain the 
seasonality in HFMD transmission in mainland 
China. However, they may have combined effects 
with school terms and the highway passenger traffic 
on the transmission rate in Anhui during the fall 
semester [66] 
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Shenzhen 
China 
Daily data 
2009 - 2017 
Air pressure, T, 
RH, RF, WS and 
SH 
DLNLM There was a facilitating on HFMD once RH varied 
46.0% to 88.8%. Short daily SH promoted HFMD. 
The positive correlation between RF and HFMD 
reversed when it exceeded 78.3mm. Ozone 
suppressed HFMD when it exceeded 104g/m3. NO2 
promoted HFMD among infants[67]  
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1.2. Virology 
HFMD is caused by several different enteroviruses. Enteroviruses (EV) are non-
enveloped, single-stranded, positive-sense RNA viruses belonging to the 
Enterovirus genus within the Picornaviridae family. They are small, 
approximately 20-30nm in diameter and icosahedral in shape. The viral genome is 
about 7.5 Kbp in length, encoding for structural and non-structural proteins called 
P1, P2 and P3. The P1 region encodes four structural proteins, including viral 
protein 1 (VP1), VP2, VP3 and VP4. A virion is comprised of 60 protomers and 
each protomer contains one VP1, VP2, VP3 and VP4 protein. VP1 is the major 
capsid protein on the surface of a virion and a major antigen, whereas VP4 is 
located internally, and is not exposed on the viral surface [5].   
   
Figure 1.6: Structure of the enterovirus virion [5]  
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Based on molecular and serological characteristics, the genus Enterovirus is 
classified into 15 different species, namely enterovirus A-L and rhinovirus A-C 
[68]. Among these species, enterovirus A-D and rhinovirus A-C are human 
pathogens. Enterovirus A serotypes have been noted as the main causes of HFMD 
and this species contains coxsackievirus A (CV-A) 2-8, 10, 12, 14, 16 and 
enterovirus A71 (EV-A71) serotypes. In the first report of HFMD pathogens from 
Canada in 1958, Robinson C.R. and Rhodes A.J revealed that coxsackievirus A 
was isolated from 71% (22/31) of tested patients and CV-A16 was detected in 3 
out of 4 cases [2]. Since then, the etiology of HFMD has changed significantly, 
with various EV serotypes circulating across the world, especially in the Asia-
Pacific region. Overall, almost all severe outbreaks with high incidence of severe 
cases and fatalities have been associated with EV-A71, while epidemics with mild 
HFMD have been attributed to different CV-As such as CV-A16, CV-A10 and 
CV-A6 [8,69–74].  
As for EV-A71, genetically, a complete VP1 sequence-based phylogenetic 
analysis conducted in 1999 reveals that there are three genogroups of EV-A71, 
namely A, B and C [5]. Genogroup A was first isolated in California (USA) in 
1969. Genogroup B and C are divided into five subgenogroups, from B1 to B5 and 
C1-C5, respectively. Viruses of genogroup B and C have been widespread and 
caused major outbreaks worldwide. However, the distribution of EV-A71 
subgenogroups differed from country to country in the last two decades, from 
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1997 to 2014. In particular, C4 was the major subgenogroup reported in China, 
with B5 sporadically reported, while other countries reported at least two 
subgenogroups circulating in the same period and/or replacing each other over 
time [8,69] (Figure 1.7). In Vietnam, C5 was responsible for the first outbreak in 
2005. However, in recent years, there has been a replacement between C4 and B5 
with C4 being responsible for the major outbreak during 2011 and 2012. 
Subgenogroup C4 also caused the severe outbreak in 2012 in Cambodia [14]. The 
distribution of EV-A71 subgenogroups from 2013 to 2018 is shown in Figure 1.8 
[18]  
 
Figure 1.7: Distribution of EV-A71 subgenogroups worldwide [73]  
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   Figure 1.8: Distribution of EV-A71 subgenogroups in Asia Pacific region [18] 
 
As for non-EV-A71 causes of HFMD, other EV A serotypes, especially CV-A6, 
A10 and A16 were reported as the most common non-EV-A71 pathogens of 
HFMD in Europe (Finland, Spain, Hungary, France, Denmark and the UK), the 
Americas (Cuba, USA) and Asia (China, India, Japan, South Korea, Malaysia, 
Singapore, Taiwan, Thailand and Vietnam) [75]. Of note, CV-A6 was mentioned 
as the predominant pathogen in Taiwan (2007-2008), China (2013), Japan (2005, 
2011) and Vietnam (2014-2015) [75,76].       
1.3. Clinical management 
1.3.1 Clinical features and case management 
HFMD is clinically characterized by a triad including fever, typical skin lesions on 
hands and feet and vesicle ulcers in the mouth, and is commonly benign and self-
limited. However, 10%-30% of hospitalized patients with EV-A71-related HFMD 
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may progress to severe complications, including central nervous system 
involvement and autonomic nervous system imbalance leading to 
cardiopulmonary failure, which may lead to severe sequelae or even death [8]. In 
addition, a wide range of other signs or symptoms have been described, from mild 
to severe grades such as: diarrhea, vomiting, myoclonic jerks, ataxia, lethargy, 
convulsion, paralysis, fast breathing, eye-wandering, hypertension, profuse 
sweating, shock and pulmonary edema [13].  
In 2011, WHO proposed guidelines on HFMD case management [8], giving a 
wide range of information on epidemiology, virology, pathology, clinical features, 
laboratory diagnosis, classification/clinical diagnosis and treatment. In brief, a 
patient is clinically diagnosed as HFMD when he/she has fever, rash on palms or 
feet and vesicles in the mouth. To guide case management, the disease is divided 
into four grades, namely uncomplicated HFMD or herpangina, HFMD with CNS 
involvement, HFMD with ANS imbalance and HFMD with cardiopulmonary 
failure (Figure 1.9).       
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Figure 1.9: WHO guidelines for HFMD case management [8] 
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In response to the 2011 outbreak, an adapted version of the Taiwanese HFMD 
classification was issued by the Vietnamese Ministry of Health (MOH) after 
consulting with experts in the field to help clinicians in their daily practice. 
Compared to WHO guideline, the Vietnamese guideline also has 4 grades, with 
increasing severity from grade 1 to grade 4. In detail, grade 1, grade 3 and grade 4 
are correspondingly similar to uncomplicated, ANS dysregulation and 
cardiopulmonary failure. However, grade 2, which corresponds to HFMD with 
CNS involvement, is divided into grade 2A, grade 2B1 and grade 2B2. In terms of 
treatment, the Vietnamese guideline showed a practical approach with 
comprehensive details to guide the management approaches (Table 1.4). More 
importantly, the guideline included hemofiltration for critically ill patients with the 
four following indications: grade 4 disease and hemodynamic instability within the 
first hour whose mean blood pressure could be maintained at at least 50 mmHg; 
coma, mechanic ventilation and uncontrolled high fever; coma, mechanic 
ventilation but hemodynamically unstable after 1-2 hours active resuscitation; 
ANS dysregulation for example fluctuation of arterial oxygen saturation, profuse 
sweating, pallor and heart rate ≥180 bpm (in a patient who is calm and not crying). 
In Vietnam, hemofiltration is not readily available in many centres and is 
considered the last-line treatment for HFMD patients with cardiopulmonary 
failure, although there is no evidence from randomized controlled trials.     
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Table 1.4: Summary of Vietnamese guideline for HFMD case management 
Clinical signs/symptoms Classification Key treatments 
One of the following 
signs/symptoms: 
 No breathing 
 Cyanosis or SpO2<92% 
 Pulmonary oedema 
 Shock 
 
 
Grade 4 
 
Severe 
cardiopulmona
ry failure 
 Transfer to ICU 
 Do intubation and mechanic 
ventilation 
 Give dobutamin 
 Do IV fluid test if shock and no 
cardiac failure while waiting for 
CVP measurement. 
 Measure CVP and give treatments 
by clinical responses and 
corresponding CVP values 
 Give Phenobarbital 10-20mg/kg/ 
slow IV 
 Give antipyretic if having high 
fever. 
 Give IVIG if mean BP ≥50 mmHg 
 Give Furosemide 1mg/kg/IV 
One of the following 
signs/symptoms: 
 Resting heart rate>170 
times/min  
 Profuse sweating  
 Hypertension 
 Fast breathing 
 Coma (GCS<10) 
 Abnormal breathing: Apnea, 
shallow breathing, chest 
indrawing, wheezing and 
stridor.  
 Un-respond pyretic fever and 
one of the following signs: 
o Ataxia 
o Nystagmus 
o Cranial nerve paralysis 
o Limb weakness  
 
 
Grade 3 
 
Cardiopulmon
ary failure 
 
 
 Transfer to ICU 
 Oxygen 1-3l/min 
 Do intubation if having abnormal 
breathing or fast breathing (>70 
times/min) or ANS imbalance or 
coma 
 Give Phenobarbital 10-
20mg/kg/IV in 30 minutes 
 Give IVIG 1g/kg/IV in 6-8 hours 
(2 doses).  
  Give Dobutamin if BP is normal 
and heart rate is >170 
times/minute. 
 Give Milrinone 0.4mg/kg/minute 
IV  
 Give antipyretic if high fever 
exists 
 Give midazolam or diazepam if 
convulsion 
 Prepare for hemofiltration if get 
worse in the first few hours and 
having one of following signs: 
o Unstable blood pressure  
o ANS imbalance exists 
o High fever and un-respond to 
active antipyretic therapies. 
Group 2: One of the following signs 
 Ataxia 
Grade 2B2 
 
 Hospitalized into inpatient wards 
 If having persistent high fever, 
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 Nystagmus or squint-eye 
 Limb weakness or flaccid 
paralysis 
 Cranial nerve paralysis 
 High fever and difficult to 
respond to active antipyretic 
therapies.  
 Heart rate >150 times/minute 
(calm and no fever). 
Severe CNS 
involvement 
give treatments as grade 3. 
 Give oxygen 1-3l/minute 
 Give Phenobarbital 10-
20mg/kg/IV for 30 minutes and 
repeat after 6 hours if myoclonic 
jerk still exists. 
 Give IVIG 1g/kg/IV for 6-8 hours 
and repeat the second dose if not 
better. 
Group 1: One of the following signs 
 Myoclonic jerk identified by 
health staff 
 Myoclonic jerk reported by 
caretakers (historical jerk) ≥ 
2times/30 minutes. 
 Historical jerk and lethargy or 
heart rate >130 times/minute 
(calm and no fever). 
Grade 2B1 
 
Severe CNS 
involvement 
 Give Phenobarbital 10-
20mg/kg/IV for 30 minutes and 
repeat after 6 hours if any 
myoclonic jerk exists. 
 Give IVIG if patient gets worse or 
did not respond to Phenobarbital 
therapy. Re-assess after 24 hours 
and consider the second dose as 
group 2B2.  
 Do lumbar puncture if having high 
fever or any meningitis possibility.  
One of the following signs: 
 Historical jerk <2 times/30 
minutes 
 Drowsiness or agitation or 
difficult to sleep 
 Fever ≥ 3 days or fever ≥390C 
 Often vomiting  
Grade 2A 
 
Mild CNS 
involvement 
 Hospitalized into inpatient wards 
 Give Phenobarbital 5-7mg/kg/day 
(P.O) 
 Counsel caretakers on warning 
signs 
Skin lesion and/or mouth ulcers 
only 
Grade 1  Ambulatory care  
 Counsel caretakers on warning 
signs 
 Follow-up every day  
 
1.3.2 Indicators of ANS dysfunction: Heart rate variability 
1.3.2.1 Overview: 
Heart rate variability (HRV), time variation between adjacent heartbeats or R-R 
intervals [77] was first described in 1960’s when Hon and Lee observed alterations 
in R-R intervals followed by fetal distress [78]. Heartbeats originate from the 
sinoatrial node which is regulated by sympathetic (SNS) and parasympathetic 
nervous systems (PNS). These two divisions of nervous system are also called 
autonomic nervous system. The interplay of PNS and SNS is dynamic, with PNS 
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dominating at rest or during digestion time whereas SNS predominates in ‘flight, 
fright, fight’ situations [78,79]. By measuring the corresponding HRV indices 
reflecting overall ANS, SNS and PNS activity, one could quantify the relationship 
between the two branches of ANS and HRV has been suggested as a noninvasive 
marker of ANS balance [78,80]. Many measures of heart rate variability have been 
suggested (see below) and by observing the effects on these following the 
application of parasympathetic or sympathetic agonists or antagonists, some have 
been suggested as particular markers of autonomic nervous system activation [78–
80]. It should be noted however that the autonomic nervous system’s regulation of 
heart rate is highly complex and occurs at many levels and affected by many 
variables. Nevertheless, there is broad consensus to approach to analysis and 
which metrics to measure [78,79,81,82]. HRV is traditionally analysed either as 
time-domain variables or as frequency-domain variables. Time domain variables 
are calculated from the distribution of R-R interval variation and include measures 
such as standard deviation, or root mean square of the standard deviation. These 
time domain measures depend upon the total number of R-R intervals and 
therefore the overall recording time. Frequency domain variables are calculated 
following Fast Fourier Transformation of the distribution resulting in a 
spectrogram of component frequencies, and arbitrary cut-offs applied to 
distinguish low, high, very low and ultra low frequencies. More recently other 
methods of analysis have been cited, for empirical mode decomposition has also 
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been advocated, where similar to Fourier Transformation, the waveform is broken 
down into component parts, although without leaving the time-domain [78,83].  
In order to standardize and allow comparison between HRV variables, guidelines 
as to which variables should be used and the optimal recording time have been 
published [77,78]. Guidelines state that frequency domain variables should be 
measured from 5-minute recordings whereas time-domain should be calculated 
from 24-hour recordings [77]. Different HRV measures thus represent underlying 
ANS activation and/or relative activity of parasympathetic and sympathetic 
components. It should be remembered that interpretation is complex and depends 
upon many factors, such as sinus node sensitivity, age, fitness and cardiovascular 
system compliance. Table 1.4 contains the most commonly cited and generally 
accepted interpretations of HRV variables.  
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Table 1.5.: Definition of HRV indices and normal range in children up to 24 months [78]  
HRV indices Definition Median [82] 
(3
rd
-97
th
 percentile)  
Time domain  
HR (beats/minute) Heart rate 105.3 (88.5-130.6) 
Standard deviation of 
NN intervals -SDNN 
(ms) 
Standard deviation of all NN intervals, a global of R-R intervals 
variability, reflects an estimate of short-term beat-to-beat variability 
[78,83]. It represents the variability over the entire recording period, 
giving the overall autonomic modulation regardless of sympathetic 
or parasympathetic arm [84]. However there are limitations 
interpreting this in short duration recordings. 
73.4 (32.7-118.5) 
Square root of 
the mean squared 
differences of successive 
NN intervals - RMSSD 
(ms) 
The square root of the mean of the sum of the squares of differences 
between adjacent NN intervals. This index measures short-term 
beat-to-beat variability and is associated with parasympathetic 
activity [83]. 
14.6 (41.4-127.3) 
Frequency domain  
Total power - Ptot (ms
2
) Five- minute total power is the variance of R-R intervals over the 4716 (1061-19692) 
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temporal segment (<4Hz) 
Very low frequency 
power - VLF (ms
2
) 
Power in very low frequency range (≤0.04 Hz). Activity is abolished 
with atropine and therefore likely to represent parasympathetic 
activity. 
938 (267-2517) 
Low frequency power-
LF (ms
2
) 
Power in low frequency range (0.04 Hz-0.15 Hz) Modulated by the 
baroreflex and representing sympathetic and parasympathetic 
activity. 
648 (122-2723) 
LF nu (%) LF power in normalized units; LF/(Total power –VLF)*100  
High frequency power-
HF (ms
2
) 
Power in high frequency range (0.15-0.4 Hz) representing 
parasympathetic (vagal activity), although can be affected by very 
high or low respiratory rates. 
700.1 (73-8508.2) 
HF nu (%) HF power in normalized units; HF/(Total power –VLF)*100  
LF/HF Ratio LF/HF 1.30 (0.50-3.33) 
Poincaré plot  
Standard deviation 1 
(Width of ellipse) - SD1 
(ms) 
 
Standard deviation of the distance of each point from the y = x axis. 
This is an index from Poincaré plot that represents short-term RR 
intervals variability [82]. It is mediated by parasympathetic nervous 
system via controlling the sinus node[85]  
26.51 (8.98-77.60) 
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Standard deviation 2 
(Length of ellipse) - SD2 
(ms)  
Standard deviation of the distance of each point from the y = x + 
average R–R interval. This is an index from Poincaré plot that 
represents long-term RR intervals variability. It reflects both 
parasympathetic and sympathetic activity 
123.84 (61.92-198.6) 
SD1/SD2 (%) Ratio of SD1 and SD2 0.222 (0.107-0.456) 
Empirical mode decomposition  
pLF1 (ms
2
) Power of low frequency band (0.1- 0.15 Hz) derived from empirical 
mode decomposition method. 
418.4 (79.5-1562.5) 
pLF2 (ms
2
) Power of low frequency band (0.04- 0.1 Hz) derived from empirical 
mode decomposition method. 
425.3 (96.0-1176.1) 
pHF1 (ms
2
) Power of high frequency band (>0.15 Hz) derived from empirical 
mode decomposition method.  
396.4 (57.8-3211.2) 
pHF2 (ms
2
) Power of high frequency band (>0.15 Hz) derived from empirical 
mode decomposition method. 
734.1 (74.3-9171.2) 
IMAI1 Ratio between pLF1 to total high frequency power (pHF1+pHF2) 
derived from empirical mode decomposition method. 
0.479 (0.189-1.113) 
IMAI2 Ratio between pLF2 to total high frequency power (pHF1+pHF2) 
derived from empirical mode decomposition method [82,84,86] 
0.551 (0.172-1.526) 
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Over the last two decades, an increasing number of HRV studies have been 
published, reporting potential applications of HRV in different fields such as 
physiology, psychology, meditation, sport training and healthcare[77,87–89]. In 
medicine, heart rate variability has been used as a non-invasive marker of ANS 
imbalance in several diseases in both adults and children[78,90–92]. There have 
been many studies citing the value of HRV in predicting outcome in ischaemic 
heart disease but in adults, recent studies also report that HRV is a predictor for 
survival in patients with cancer [92],  sepsis [82]. sudden death [93] or diabetes 
mellitus [94]. It also correlated  with inflammation markers and albumin levels in 
patients with systemic lupus erythematosus [95].  
1.3.2.2 HRV in pediatric population  
In children, several studies of HRV have been conducted, focusing on different 
aspects such as neurodevelopment [96,97], ANS maturation [82], inflammation 
[98], immunization [99], obesity [100] and infectious diseases [80,101–104]. 
There were a limited number of studies on HRV in children with infectious 
diseases. Thus, I will focus the literature review on HRV in children with 
infectious diseases including sepsis, dengue and HFMD.   
In terms of sepsis, HRV indices were identified as a predictor for mortality in 
adult patients [80]. However, in the paediatric population, few studies have looked 
at the relationship between sepsis and changes in HRV indices although a lot of 
studies have reported the association between heart rate characteristics and severe 
outcomes of sepsis [105,106]. A study enrolling 30 children aged 1 month to 18 
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years old, who were treated in a pediatric Intensive Care Unit in the US, revealed 
that LF and HF values of the sepsis group were significantly lower than that of 
septic shock while the difference in LF/HF ratio between the two groups was not 
statistically significant [107].      
With respect to dengue fever, in 35 Thai children with mean age 11.7 years, 
changes in HRV indices between the convalescent stage and recovery were 
described. The results showed that there was no statistically significant difference 
in the averaged RR interval, the time-domain HRV (SDNN, RMSSD, pNN50) or 
frequency-domain HRV (LF, HF, LF/HF ratio) between the convalescent stage 
and recovery [101]. However, the sample size of this study was small, thereby 
affecting power of paired t-test. Another study conducted in 27 Thai children with 
dengue fever aged from 6 months to 15 years old, which collected ECG signal at 
Day 0, 1 and 2 after admission, revealed that means of HF, LF significantly 
increased from 194, 249 (ms
2
) on Day 0 to 824 and 1060 ms
2
 on Day 2, 
respectively. However, LF/HF ratio reduced from 8.2 to 2.4 on corresponding 
days [102]. In summary, in children with Dengue, there was imbalance of ANS 
and it steadily decreased after 2 days admission while ANS activation slightly 
changed between convalescent stage and 14 day-follow up.  
In children with HFMD, HRV indices were first described in 40 Taiwanese 
children in 2006 in comparison with 20 healthy controls [104]. HFMD patients 
were divided into three groups with different severities. The results showed that 
there was a downward trend of SDNN, RMSSD, Ptot, LF and HF corresponding to 
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the higher severity of HFMD and the difference among these groups was 
statistically significant. In contrast, LF/HF ratio increased from 2.17 in stage I to 
4.96 in stage III, but their significant difference among these groups was not 
observed. Although potential implications for prediction of severe disease have 
been noted, the number of severe patients with autonomic imbalances was small, 
which may pose considerable bias to HRV indices. Moreover, in this study HRV 
indices were taken from a single 5 minute Holter-monitor recording and from a 
population with HFMD but not differentiated according to pathogen. Since then, 
no additional studies have been reported. Nevertheless further knowledge 
regarding HRV may help clinicians to improve their ability in early detection of 
severe HFMD, thereby improving patient management and outcome.     
1.4. Laboratory diagnosis 
As for other viral infections, virus isolation is traditionally considered as the ‘gold 
standard’. However, because of its low sensitivity, virus isolation is not considered 
for routine diagnosis nowadays. Serological testing is not recommended for 
HFMD diagnosis because second blood sample is needed to demonstrate the 
seroconversion, and the specificity of commonly used methods such as ELISA is 
low [8].  Meanwhile, PCR detection of viral nucleic acids in clinical specimens is 
more sensitive and high throughput. It is therefore a method of choice for both 
outbreak situation and clinical setting [8,108,109]. Detection of HFMD causing 
enteroviruses can be achieved by generic PCR targeted at the 5’-untranslated 
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region (5’ UTR), while viral protein 1 (VP1) region is more variable and is 
therefore more useful for serotyping purpose (i.e. detection of specific enterovirus 
serotypes in clinical specimens and subgenogroup determination in case of EV-
A71). The clinical specificity and sensitivity of PCR results are clinical specimen 
type dependent [109,110]. Due to the likelihood of coincidental carriage in 
gastrointestinal tract, virus detection in throat and rectal swabs is less reliable than 
that from sterile sites, such as plasma, cerebrospinal fluid (CSF) and vesicular 
fluid. However, because swabs are easily obtained, they are still the recommended 
samples for HFMD diagnosis [108,109]. 
1.5. Vaccines  
With the success of the ongoing poliomyelitis elimination program, vaccine is 
considered as the best effective way to control HFMD. There are currently several 
approaches to produce vaccines, based on characteristics of antigens, such as 
inactivated whole cell vaccine, attenuated live vaccine, synthetic peptide vaccine, 
recombinant vaccine, virus like particle – based vaccine.  
Because EV-A71 is the main cause of severe HFMD, especially in recent 
outbreaks in the Asia-Pacific region, attention has focused on the development of 
EV-A71 vaccines. To date, only inactivated whole EV-A71 vaccines have been 
studied in humans while vaccines for other HFMD pathogens such as CV-A6, CV-
A10 and CV-A16 have not gone beyond animal models [111].   
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Currently, there are a total of five inactivated whole EV-A71 vaccines produced 
by different companies from China, Taiwan and Singapore. Of these, three 
vaccines using subgenogroup C4 as virus seeds have been tested in three different 
phase 3-trials in China. The overall efficacy against EV-A71-associated HFMD of 
the three vaccines varied from 89% to 97% [112,113] and no serious adverse event 
was reported. These vaccines were approved by the China Food and Drug 
Administration in 2015 and have been used in only some parts of mainland China 
[114,115]. In contrast, the other two inactivated whole EV-A71 vaccines using 
viruses of subgenogroup B4 produced in Taiwan have completed phase 2 trials 
and one phase 3-trial has been conducted in southern provinces of Vietnam 
[115,116].  
With high efficacy against the most important pathogen of HFMD, it is likely that 
these inactivated whole EV-A71 vaccines will be implemented in Vietnam and the 
region. However, to provide baseline data before introducing vaccines, 
synthesizing data on economic burden of HFMD is essential to inform health 
policy makers in these countries. 
1.6. Economic burden 
HFMD has become a public health concern in the Asia-Pacific region. It poses a 
significant burden on the community when large outbreaks occur. Parents of 
affected children have to take time off from work in order to take care of their 
child due to hospitalization and/or school/kindergarten closure. Uncertainty over 
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which children will progress to severe disease means many children must be 
admitted to hospital for observation, placing even more pressure on already 
strained resources. Cost of illness (COI) is one measure of burden of a disease, 
measuring impact of the disease on a community in terms of prevalence, 
incidence, morbidity, mortality and various aspects of health economics [117–
119]. A critical aim of a cost of illness study is usually to estimate direct costs, 
indirect costs, premature deaths and productivity losses. A COI study can be 
conducted using different approaches and/or under various perspectives. 
Consequently, the study results greatly vary on the methods employed and the 
designs of such studies are dependent on researchers’ perspectives [120].  
There are currently various approaches to calculate cost of illness of HFMD, using 
different methods and from different perspectives [121–124]. For example, from 
the society perspective, a Taiwanese study revealed that annual expenditures 
incurred by national health insurance was $526 to $557 million ($475-567 per 
capita), constituting 1.1% to 3.7% of national health insurance spending. For 
indirect costs which include travel cost, productivity cost and productivity losses 
due to premature mortality, total cost of the first two was $37.1 million per year, 
of which, costs of EV-A71 accounted for 5% of total costs due to enteroviruses 
associated with HFMD. The productivity losses from premature deaths were $0.8 
million a year, with EV-A71 being in charge of 96.3% [31]. Another study in 
which productivity losses from premature deaths were not included in indirect 
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costs reported that the economic burden of HFMD incurred by a population of 
1.42 million children was $7.66 million and the mean cost per case was $208.2. In 
outpatients, the direct mean costs were $56.7 and indirect mean costs were $108.6. 
In hospitalized patients with mild disease, mean direct costs were $550.3 and 
indirect costs were $309.5. In severe HFMD, the direct mean cost was more than 
double that of the indirect one, at around $1500 and indirect costs were $650  
[124].       
Despite the high incidence of HFMD in Vietnam, there are no reports about the 
associated cost of illness posed by HFMD. Such knowledge is essential for health 
policy makers for planning and budgeting of resources for disease management, 
prioritizing vaccine development and implementation of interventional strategies 
in response to disease outbreaks.  
1.7. Hypotheses and research questions  
From the literature review as aforementioned, I have identified several important 
knowledge gaps, where a better understanding could lead to improved 
preventative measures and treatments of HFMD. Whilst these focus on Ho Chi 
Minh City, where there is a significant burden of HFMD, better understanding is 
of value to HFMD management throughout the world.  
Specifically, I hypothesize that: 
1. The ongoing epidemic of HFMD in southern Vietnam, especially in Ho Chi 
Minh City, is complex and is driven the emergence of pathogens. 
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2. HRV indices are different between HFMD patients infected with different 
viruses and/or presenting with different clinical severities. 
3. HFMD causes high economic burden in Vietnam. 
Accordingly, my research questions are: 
Epidemiology:  
 What is the spatial-temporal distribution of HFMD in Ho Chi Minh City 
between 2005 and 2015?  
 What are the most common pathogens associated with HFMD during 
2015 – 2018?  
Heart rate variability: 
 Is it possible to use wearable devices such as E-patch to identify HRV 
indices in children with HFMD? 
 Is there any statistically significant difference in values of HRV indices 
among disease severities or between the most common detected 
pathogens? 
Economic burden: 
 What are the cost units of different grades of HFMD in Vietnam?  
 What are the costs of HFMD caused by the most common HFMD 
pathogens in Vietnam?  
 What is the total economic burden that HFMD posed to society in 
Vietnam during 2016 – 2017? 
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Chapter 2 
Epidemiology, and temporal and spatial distributions of hospitalised  
hand, foot and mouth disease cases in Ho Chi Minh City, Vietnam 
between 2005 and 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
2.1 Background 
 
Vietnam has a rapidly urbanizing population. Ho Chi Minh City is the most 
populous city in Southern Vietnam with a population of approximately 13 million. 
The city is divided into 24 administrative districts, which are further subdivided 
into 322 wards. On average, each ward has around 40,000 residents. Ho Chi Minh 
City is one of the most densely populated cities in the world with an average 
population density of over 6200 inhabitants per square kilometers [125]. HFMD is 
a communicable disease, transferred through fecal oral transmission and  
managing HFMD outbreaks in such dense urban populations has proved extremely 
challenging. Furthermore, there are limited data describing geographical spread 
HFMD in HCMC which could be used to guide public health policy. The limited 
existing data were collected in outbreak-related studies and are therefore 
inherently biased because of the time and resources available for the studies 
[21,40]. Disease notification data is also limited as it does not contain data about 
residency, and potentially duplicates data in HFMD cases to initially admit to local 
health care centers and then transferred to major hospitals. As such a better 
understanding of epidemiology and spatial and temporal distribution of HFMD in 
this dynamic setting remains fundamental to understanding this emerging infection 
and guiding further research in coming years. Herein, I aim to provide a general 
picture about these aspects of HFMD in HCMC over 11 years (from 2005 to 
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2015), preceding the prospective hospital-based study I conducted during the 
period of my PhD study (Chapter 3).     
2.2 Materials and Methods 
2.2.1 Hospitalized HFMD data and study settings  
 
Figure 2.1: Map of a part of HCMC locating CH1, CH2 and HTD in red.  
  
HFMD data were derived from hospitalized cases at 3 major hospitals in Ho Chi 
Minh City: Children’s Hospital 1 (CH1), Children’s Hospital 2 (CH2) and 
Hospital for Tropical Diseases in Ho Chi Minh City (HTD). These three hospitals 
have been responsible for treatment of the vast majority of hospitalized HFMD 
cases from Ho Chi Minh City and severe cases from the southern provinces of 
Vietnam.  
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CH1 was established in 1956 and is the highest level of pediatrics in South of 
Vietnam, with 1400 beds and 23 clinical departments in inpatient area and 63 
consultation rooms in outpatient clinic. Although located in Ho Chi Minh City, 
CH1 provides child healthcare services for around 20 provinces (from Binh Thuan 
to Ca Mau) in south of Vietnam with an estimated population of 42.3 million 
people. On average, CH1 receives 1.8 million outpatients and 100.000 inpatient 
admissions a year. Of these, 60% of outpatients come from Ho Chi Minh City and 
40% from southern provinces whereas these figures for inpatients are 
approximately 70% and 30%, respectively. All studies in this thesis were 
conducted in Outpatient Clinic, Infectious Disease Department (IDD) and 
Intensive Care Unit (ICU) of this hospital. According to CH1’s guidelines, IDD is 
responsible for treating HFMD patients with grade 1, grade 2 and grade 3 while 
ICU is in charge of receiving critically severe HFMD cases including patients 
needing mechanical ventilation and/or hemofiltration. 
CH2 was established in 1978 and is the referral pediatric hospital at the same level 
with CH1. The catchment area of CH2 is mainly provinces located in south-east of 
Ho Chi Minh City and Central Vietnam. CH2 has similar pediatric specialties to 
those available at CH1 and also a comparable number of outpatients and inpatients 
to CH1.  
HTD is the highest level hospital in terms of infectious diseases in Vietnam’s 
southern provinces, providing health care for both children and adults with tropical 
diseases. The hospital has a total of 550 beds including 200 beds for children 
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under 16 years old. On average, there are 1700 patients seen in the hospital 
outpatient department each day. Approximately 600,000 patients are admitted 
each year.  
2.2.2 Study design 
This is a retrospective study using available data from the health informatics 
systems of CH1, CH2 and HTD.  
2.2.3 Data collection 
Individual data of HFMD patients, who were under 16 years of age, lived in Ho 
Chi Minh City and admitted to Children’s Hospital 1 (CH1), Children’s Hospital 2 
(CH2) and the Hospital for Tropical Diseases (HTD) between 1 January 2005 and 
31 December 2015 were extracted from the health information database of the 
three hospitals. Extraction of the HFMD data was based on the 10
th
 revision of the 
International Statistical Classification of Diseases and Related Health Problems 
(ICD-10), with codes of HFMD being B08.4 or B08.4-1 or B08.4-2A or B08.4-2B 
or B08.4-3 or B08.4-4. Information extracted consisted of date of birth, date of 
admission, patients’ address provided by accompanying relatives, gender, 
diagnostics on admission and at discharge, and discharge outcomes.   
Although the aforementioned hospitals are located in urban districts of HCMC and 
only 10 kilometers apart, the three hospitals are not only responsible for treatment 
of patients from HCMC but also receive sick children with HFMD, especially 
those with severe disease, from other provinces in south of Vietnam. For high 
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resolution of the mapping analysis, here we focused our analysis on data from 
patients coming from Ho Chi Minh City only, defined as living within one of the 
24 districts of Ho Chi Minh City. 
 
Figure 2.2: Ho Chi Minh City map and population density at commune level 
in 2017 
 
2.2.4 Methodology for mapping analysis 
Mean center, standard distance and directional distribution (standard deviational 
ellipse) were employed to depict the characteristics of spatial distribution of 
HFMD in Ho Chi Minh City, using ArcGIS software version 10.3. To understand 
the patterns of disease spread maps were used to illustrate the distribution of 
HFMD cases by wards and years.  
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In this study, each ward is represented by a point located in the centre of ward. 
This central point has its own coordinate including X and Y. The mean center is a 
point generated by taking the average of X and Y coordinates of all central points. 
While a mean center is similar to a geometric mean in traditional statistics, a 
standard distance is equivalent to a standard deviation (SD) describing to what 
extent points disperse around a mean center. A standard distance is displayed by a 
circle having inside 68% (1SD), 95% (2SD) or 99% (3SD) of total points in a 
map. By looking at the mean center and standard distance, characteristics of a 
spatial distribution can be assessed. In addition to this, a standard deviational 
ellipse which measures the pattern for a set of points is used to determine a 
directional distribution of a feature. Here is the orientation spread of HFMD in 
HCMC [126,127].  
2.2.5 Ethics 
The Institutional Review Board of CH1, CH2 and HTD, and the Oxford Tropical 
Research Ethics Committee (OxTREC) approved the study.  
2.3 Results 
2.3.1 Characteristics of all hospitalized HFMD patients  
Over an 11-year period, between January 2005 and December 2015, there were a 
total of 56,048 patients living in HCMC admitted to the three aforementioned 
hospitals, including 25,057 (44.7%) admitted to CH1, 16,575 (29.6%) admitted to 
CH2 and 14,416 (25.7%) admitted to HTD. Male patients accounted for 60.8% 
(34,072/56,048). The predominance of males was relatively consistent during the 
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study period (i.e. before, during and after the major outbreak occurring in 2011-
12). A total of 74 patients were recorded as decease, accounting for 0.13% of the 
total hospitalized cases, with the peak number of 35 cases recorded in 2011 – 2012 
during the large-scale outbreak [40]. There were 23,017 cases without a specific 
grade recorded. Of the remaining patients, 5,650 patients had grade 1, 25,608 had 
grade 2A, 1225 had grade 2B, 489 had grade 3 and 59 had grade 4. While the 
majority of hospitalized patients during 2005-2010 have no clinical grade 
available for comparison, the distribution of clinical grades was relatively similar 
between the periods 2011-12 and 2013-15. The number of patients under 1, from 
>1 to 5 and > 5 years old was 11998 (21.4%), 42997 (76.7%) and 959 (1.7%), 
respectively (Table 2.1). The age structure of hospitalized cases was comparable 
during the study period (i.e. before, during and after the major outbreak occurring 
during 2011-12). 
Table 2.1: Characteristics of study population 
Variables All  
(n=56048) 
2005-2010 
(n=10918) 
2011-2012 
(n=23467) 
2013-2015 
(n=21663) 
Age (months) 
Median (IQR)  
18 (12-25.2) 18 (12-25.2) 18 (12-26.4) 16.8 (12-24) 
Age groups     
- < 12 months 
- 12-24 
- 25-36 
- 37-60 
- >60 
11998 (21.4) 
28944 (51.6) 
9833 (17.5) 
4220 (7.5) 
959 (1.7) 
2105 (19.3) 
5942 (54.4) 
1929 (17.7) 
760 (7.0) 
119 (1.1) 
4971 (21.2) 
11599 (49.4) 
4437 (18.9) 
1987 (8.5) 
456 (1.9) 
4922 (22.7) 
11403 (52.6) 
3467 (16.0) 
1473 (6.8) 
384 (1.8) 
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- Unknown 94 (0.2) 63 (0.6) 17 (0.1) 14 (0.1) 
Gender (n, %) 
- Male  
- Female 
 
34072 (60.8) 
21976 (39.2) 
 
6816 (62.4) 
4102 (37.6) 
 
14200 (60.5) 
9267 (39.5) 
 
13056 (60.3) 
8607 (39.7) 
Clinical grade     
- 1 5650 (10.1) 1358 (12.4) 3022 (12.9) 1270 (5.9) 
- 2A 25608 (45.7) 753 (6.9) 10151 (43.3) 14704 (67.9) 
- 2B 1225 (2.2) 0 824 (3.5) 401 (1.9) 
- 3 490 (0.9) 1 261 (1.1) 227 (1) 
- 4 58 (0.1) 0 47 (0.2) 12 (0.1) 
- Non specific 23017 (41.1) 8806 (80.7) 9162 (39) 5049 (23.3) 
Fatal outcome 74 (0.1) 36 (0.3) 35 (0.1) 3 
 
2.3.2 Temporal distribution of hospitalized HFMD cases in Ho Chi Minh City 
The total number of hospitalized HFMD cases observed increased each year from 
2005 to 2012, beginning at 294 in 2005, reaching 2,930 in 2010, and then 
increasing to 12,112 in 2011 and 11,355 in 2012 (Figure 2.1). From 2013 to 2015, 
an average of around 7,200 hospitalized HFMD cases was recorded. The peak 
number of cases a month occurred in September – December in 9 out of the 11 
years of the data. In 2008 and 2011, the peak occurred in May and June 
respectively. 
2.3.3 Spatial distribution of HFMD cases in Ho Chi Minh City 
The Figure 2.2 shows annual cases in each district over the 11-year period. In 
general, it is obvious that there was an upward trend in the number of HFMD 
hospitalized cases in all districts over the study period, with the highest peaks in 
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2011 and 2012. Compared to the overall average data for the entire 11-year period, 
24 districts of the city could be classified into three groups. The first group 
including Binh Chanh, District 8 and Binh Tan had significant greater number of 
cases than that of other districts. The second group consisting of District 6, District 
12, Go Vap, Tan Binh, Tan Phu and Hoc Mon had slight higher number of cases 
than that of the third group. 
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Figure 2.3: Temporal distribution of HFMD in HCMC, Vietnam from 2005 to 2015
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Figure 2.4: Distribution of HFMD cases by district from 2005 to 2015 
Note to Figure 2.4: D1: District 1, D2: District 2, D3: District 3, D4: District 4, D5: District 5, D6: District 6, D7: District 7, 
D8: District 8, D9: District 9, D10: District 10, D11: District 11, D12: District 12, BT: Binh Tan District, BTh: Binh Thanh 
District, GV: Go Vap District, PN: Phu Nhuan District, TB: Tan Binh District, TP: Tan Phu District, TD: Thu Duc District, 
BC: Binh Chanh District, CC: Cu Chi District, CG: Can Gio District, HM: Hoc Mon District, NB: Nha Be District  
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In terms of mapping analysis, the Figure 2.3 shows the distribution of HFMD 
hospitalized cases in Ho Chi Minh City over the 11-year period, with location unit 
being ward. It is clear that the turning point of the HFMD trend was 2008 when 
the disease spread to the south-east of the city where there were several wards with 
high numbers of cases (Figure 2.3). As a result, the mean center moved to the east 
at the coordinate of 106.682, 10.791. For the next two years, HFMD cases moved 
to the west again, coinciding with the unprecedented outbreak in 2011 and 2012 
with the vast majority of wards in the city, especially those in the west, affected. 
After 2012 the disease mostly existed in the west of the city, with a steady 
decrease in the number of cases for the last three years of the study period.     
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Figure 2.5: Spatial-temporal distribution of HFMD cases in HCMC, Vietnam, from 2005 to 2015. 
Note to Figure 2.5: The red point, violet circle and pink ellipse represented the mean center, 01SD distance deviation 
and directional distribution, respectively.  
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2.4 Discussion 
HFMD has been a notifiable disease in Vietnam since 2005, primarily being 
observed in southern provinces with HCMC being the major hotspot. Here I 
described the epidemiology and reconstructed the temporal and spatial 
distributions of hospitalized HFMD cases in HCMC over an 11-year period in 
HCMC.  
2.4.1 Characteristics of HFMD hospitalized cases 
Our study found that HFMD was more likely to be observed in males, with 
proportion at around 60%, consistent with previous reports [21,39,128], and 
findings from other infectious diseases (e.g. dengue) in Vietnam and the region. It 
may suggest that besides host immune status and hygienic condition, behavior 
may be the main factor to explain why males had a higher risk of HFMD infection 
[128]. It has been suggested that boys, in Vietnam particularly, may have more 
interactions with others (e.g. adults) because presumably they often receive more 
attention from relatives and others, and  tend to be more active than girls, 
proposing higher exposure to contaminated surfaces, toys, or fomites [5,128]. In 
relation to age distribution, our finding consistently showed that 98% of cases 
were under 5 years old with 21% were under 1 year. This finding is agreement 
with previous reports [21,22,128,129]. However, the proportion of infants in our 
study was nearly double that of the study conducted in Henan-China in which this 
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figure was reported at around 10% [130]. This discrepancy may be because of 
different host and/or community immune status, socioeconomic factors and 
climatic factors, and/or the difference in design of the respective studies [41,49]. 
In terms of fatal outcome, there were a total of 74 deaths over 11-year period, with 
the majority of cases occurring before 2013 (71/74) and half of the cases attributed 
to the 2011-12 outbreak. This may be related to three factors. First, health staff 
may lack experience in identification and treatment of HFMD, especially 
physicians working in primary  health facilities. As a consequence, this may lead 
to delayed admission to the three referral hospitals or presentation at these 
hospitals in severe stages of disease [3]. Secondly, there may have been changes in 
the virulence of pathogens causing HFMD over the study period. It was reported 
that EV-A71 and CV-A16 were the most common pathogens of HFMD before 
2011 and EV-A71 was responsible for 3 deaths among 764 hospitalized cases in 
CH1 [21]. After that EV-A71 was detected in a high proportion of hospitalized 
cases and deaths during the large-scale outbreak in 2011-2012 [3,40]. From 2013 
to 2015 alongside with EV-A71 (identified in 24.4% of cases), CV-A6, CV-A10 
and CV-A16 were detected in 21.8%, 7.9% and 10.8% of cases respectively. The 
third possible explanation for the lower mortality is that, the healthcare system 
itself has been strengthened after the large outbreak and activities such as staff 
training and updated guidelines have led to improved outcomes.                
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2.4.2 Temporal and spatial distribution of HFMD hospitalized cases 
Our results showed that the HFMD epidemic in HCMC started in wards located in 
the west of the city. The directional spread of the disease from the north-west to 
the south-east between 2005 and 2007, followed by the spread to the west and the 
south of the city in 2008 may be attributable to several factors. Firstly, the wards 
in the west of the city may have had higher numbers of vulnerable subjects (i.e. 
young children) than the other wards (the 2017 population of the west, east, north, 
south and central districts was approximately 3.7, 0.62, 2.48, 0.7 and 0.84 million, 
respectively)[131]. Secondly, these wards have borders with Long An province, 
which is part of the Mekong Delta River Region, which has been the source of 
several circulating infectious disease outbreaks such as hand, foot and mouth 
disease, dengue, typhoid, Japanese encephalitis and others[49,131]. Due to the 
living cost and job opportunities, the immigrants from this region may tend to 
choose the nearer districts to live when they come to HCMC for the first time. 
Lastly, people, including adults who also contribute to the transmission chains of 
HFMD, are perhaps more likely to move towards the center of the city for their 
work and education, possibly making HFMD spread to the eastern districts. 
The exact reasons for the spread of HFMD in 2009 and 2010 are unknown. At this 
time HFMD  spread back to the west and attacked several new wards in the north 
and centre of the city. This may have been a consequence of public health 
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response, herd immunity or pathogen emergence combined. Of note, we have 
recently report the emergence of CV-A6 in Vietnam [23,76], which was identified 
to be circulating in the southern Vietnam some time in 2010 prior to emergence in 
2012-2013.   
The large-scale outbreak occurred at a citywide level in Ho Chi Minh City in 2011 
and 2012, with more than 23,000 admissions and 35 deaths. The main cause of the 
outbreak was EV-A71[3,23,40,132], which also caused various severe outbreaks 
in Taiwan, Malaysia, Korea, Japan and China [5,21]. The epidemic cycle pattern 
of HFMD in HCMC however differs from that in Taiwan, Japan and Malaysia. 
While Taiwan, Japan and Malaysia had a pattern of 2-3 yearly outbreaks, HFMD 
has been observed annually in Vietnam [5,21]. The occasionally observed two 
peaks per year of HFMD may have been attributed to the circulation and 
replacement of dominant HFMD causing enterovirus serotypes with CV-A being 
dominant in the first part- and EV-A71 in the second part of the year [21,76].  
2.4.3 Limitations and future plans 
Despite a holistic effort looking at the epidemiology of HFMD over an 11-year 
period in the most populous city in Vietnam, our study has some limitations. First, 
only admission data from 3 hospitals were used and it is likely that the total 
number of cases is much higher than reported, especially that of mild disease. 
However by confining our study to hospitalized cases we ensured more accurate 
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diagnoses and also concentrated on the disease severity that presents the greatest 
public health burden. Furthermore the hospitals we included are specialist 
hospitals with experienced staff making the accurate diagnosis of HFMD more 
likely. This study also did not explore effect of population movement on HFMD 
transmission because it is currently estimated that there are at least two million 
non-residents who enter and leave HCMC every day. These people may bring 
HFMD to the city or spread the disease to other provinces, but focusing our 
analysis only on HCMC residents may have reduced sensitivity to detect important 
patterns here. Further limitations are that due to the unavailability of the data, I did 
not taken into account factors such as climatic variables, socioeconomic factors, 
the pathogens and co-variables (population size), especially the proportion of 
children less than 5 years old, for the spatial analysis. Ideally these would be 
included in future studies if data can be obtained.  
2.5 Conclusion  
The present study highlights a significant burden posed by the ongoing HFMD 
epidemic in HCMC, a metropolitan city of Vietnam over 11 years, with an 
increasing number of hospitalized cases, especially during the last 5 years of the 
study period (2011-15). Despite the upward trend of the reported cases, it was 
relatively consistent that districts located in the west of the city often acted as the 
main ‘hotspots’ of the epidemic, which merits further research. Likewise, because 
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of its burden, research to unravel important aspects on etiology, clinical 
characteristics, economic burden and disease pathophysiology of this emerging 
infection remains essential for outbreak response, the development of intervention 
strategies (e.g. vaccines) and clinical management. 
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Chapter 3 
Clinical, etiological and epidemiological investigation of hand, foot and 
mouth disease in southern Vietnam during 2015 – 2018 
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3.1 Background 
Given the high endemicity and the complex epidemic dynamics of HFMD, 
synthesizing clinical, epidemiology and etiology of this emerging infection 
remains essential to inform the development of appropriate interventions 
(including vaccines) and design public health measures in order to reduce its 
global burden. As such since 2013, a comprehensive hospital based study has been 
conducted at three major hospitals in Ho Chi Minh City aiming at capturing long-
term data on these aspects of this emerging infection [21,76,133,134]. Herein, I 
report the results of my investigations for the period during 2015 – 2018, covering 
the most recent severe HFMD outbreak recently documented in Vietnam [135]. 
3.2 Materials and Methods 
3.2.1 Settings 
The clinical and patient data used in the present study were derived from an 
ongoing clinical study of HFMD, which has been conducted at the Hospital for 
Tropical Diseases (HTD), Children’s Hospital 1 (CH1) and Children’s Hospital 2 
(CH2) in Ho Chi Minh City, Vietnam since 2013 [134,135]. The results of the first 
part of the clinical study for the period from July 2013 to July 2015 have 
previously been reported elsewhere [134]. Here, I focus on analysis for the period 
from August 2015 to December 2018. 
3.2.2 Patient enrollment and data collection  
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Any patient ≤12 years of age presenting to outpatient departments or admitted to 
inpatient wards of the three participating hospitals with a clinical diagnosis of 
HFMD and, if outpatients, an illness day of ≤3 days for enrolment in our study 
was eligible to participate in the study. Patients were excluded if the attending 
physician believed another diagnosis was more likely. Because of the waning of 
the epidemic in 2017 and the availability of the resources, from January to 
December 2018, patient recruitment focus was reduced to CH1 site.  
Collected information included demographic, clinical signs/symptoms (including 
clinical grades) on enrolment to the study and (if inpatients) daily until discharge 
or day seven of hospitalization (whichever came first), treatments, laboratory tests, 
length of hospital stay (inpatients only), and outcomes. Additionally, for 
virological assessments, an acute throat swab and rectal swab were collected at 
enrolment from each participant.   
3.2.3 Determination of enterovirus serotype and EV-A71 subgenogroup  
Enterovirus serotypes determination was carried out using a combination of PCR 
and sequencing approaches [109,136,137] (Figure 3.1). In brief, viral RNA was 
first extracted from throat swabs collected from the study participants using a 
QIAamp viral RNA kit (Qiagen GmbH, Hilden, Germany). Extracted viral RNA 
was then analysed using a one-step multiplex real-time RT-PCR assay to 
simultaneously detect enteroviruses and EV-A71 in the extracted NA materials 
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[109]. All specimens positive for enterovirus serotypes or EV-A71 were then 
tested to further identify specific enterovirus serotypes or EV-A71 subgenogroups, 
respectively, using a combination of VP1 PCR amplification and sequencing of 
the obtained PCR amplicon [40,136,137]. Finally, the obtained VP1 sequences 
were then analyzed using a previously described online tool to determine 
enterovirus serotype or EV-A71 subgenogroup [138]. In case the one-step 
multiplex real-time RT-PCR analysis of the throat samples gave a negative result, 
rectal swabs were further analyzed, and if positive, the same subsequent steps 
were repeated to identify enterovirus serotypes or EV-A71 subgenogroups [109]. 
All primers and probes used are listed in Table 3.1, and the detailed PCR and 
sequencing procedures are presented in Appendix 1. 
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Figure 3.1: Flow chart outlining the procedure applied for enterovirus 
detection in clinical samples and serotyping of enteroviruses. 
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Primers and probes used for primary screening of clinical samples [109] 
Name Sequence (5’→3’) Position Note 
ENT-F CCCTGAATGCGGCTAAT 452 - 468  
ENT-R ATTGTCACCATAAGCAGCC 579 - 597  
ENTr-probe Cy5-ACCCAAAGTAGTCGGTTCCG -BHQ3 531 - 551  
EAV-F primer CATCTCTTGCTTTGCTCCTTAG 1847–1868  
EAV-R primer AGCCGCACCTTCACATTG 1980–1997  
EAV-probe FAM-CGCTGTCAGAACAACATTATTGCCCAC-BHQ1 1926–1964  
EV-A71-634 F GGAGAACACAARCARGAGAAAGA 634 - 656  
EV-A71-743R ACYAAAGGGTACTTGGAYTTVGA 721 - 743  
EV-A71-probe Cyan500-TGATGGGCACDTTCTCRGTGCG-BHQ1 686 - 707  
Primers used for enterovirus serotyping [136] 
Name Sequence (5’→3’) Position Note 
SO224 GCIATGYTIGGIACICAYRT 1977 - 1996 1
st
 round RT-PCR 
SO222 CICCIGGIGGIAYRWACAT 2969 - 2951 1
st
 round RT-PCR 
AN32 GTYTGCCA 3009 - 3002 1
st
 round RT-PCR 
AN33 GAYTGCCA 3009 - 3002 1
st
 round RT-PCR 
Table 3.1: List of oligo sequences used for simultaneous detection, serotyping of EVs or genotyping of EV-A71 
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AN34 CCRTCRTA 3111 - 3104 1
st
 round RT-PCR 
AN35 RCTYTGCCA 3009 - 3002 1
st
 round RT-PCR 
AN89 CCAGCACTGACAGCAGYNGARAYNGG 2602 - 2627 2
nd
 round PCR (forward) 
AN88 TACTGGACCACCTGGNGGNAYRWACAT 2977 - 2951 2
nd
 round PCR (reverse) 
AN232 CCAGCACTGACAGCA 2602 - 2616 Sequencing 
AN233 TACTGGACCACCTGG 2977 - 2963 Sequencing  
Primers used for enterovirus A71 genotyping [40] 
Name Sequence (5’→3’) Position Note 
EV71-VP1-3F AGAYAGGGTGGCRGATGT 2462 - 2445  
EV71-VP1-703R CTGAGAACGTGCCCATCA 3125 3142  
Note to Table 3.1: EAV: Equine arteritis virus, which serves internal control; (FAM = Carboxyfluorescein; Cy5 = Cyanine 5; 
Cyan500 = Cyan 500 NHS ester; BHQ = black hole quencher; R = A and G; Y = T and C; V = A, C, and G; D = A, G, and T) 
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3.2.4 Phenotypic comparison between major subgenogroups of EV-A71 
The abovementioned clinical study has been sampling HFMD cases since July 
2013. As such, this gave me a unique opportunity to capture the transition between 
predominant subgenogroups of EV-A71 in Vietnam over a period of 6 years (2013 
- 2018). To assess the differences in clinical phenotypes between subgenogroups 
of EV-A71, I used a combined dataset of the first- and the second phases of the 
clinical study (i.e. during July 2013-July 2015 and August 2015-December 2018, 
respectively).  
3.2.5 Statistical analysis 
Data was analysed using IBM Statistical Package for Social Sciences (SPSS) 
Version 23.0. A P value of less than 0.05 (P < 0.05) was considered to be 
statistically significant. 
3.2.6 Ethical statement 
The Institutional Review Board of CH1, CH2 and HTD, and the Oxford Tropical 
Research Ethics Committee (OxTREC) approved the study. Written informed 
consent was obtained from a parent or legal guardian of each enrolled patients. 
3.3 Results 
3.3.1 Baseline characteristics of all patients, and in- and outpatients  
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During August 2015 – December 2018, a total of 1196 children presenting with 
clinically suspected HFMD were enrolled in the clinical study. The majority of the 
participants were young children, with median age of 18.7 months (range 2.4 – 
118.2), and predominantly males (male/female: 746/450). Nearly half (n=568, 
47.5%) of the patients were from Ho Chi Minh City. In terms of clinical 
phenotypes, 281 (23.5%) patients had severe HFMD, comprised of 71 cases with 
grade 2B1, 68 cases with grade 2B2, 136 cases with grade 3 and six cases with 
grade 4. Milrinon, magnesium sulfate and intravenous immunoglobulin were 
given to 69 (5.8%), 1 (0.1%) and 215 (18.0%) patients, respectively (Table 3.2). 
At discharge, unfavorable outcomes were recorded in 15 patients (1.25%), 
including three deaths (0.25%) and 12 with complications or underlying diseases 
(1%). Additional details about the study participants are presented in Table 3.2.   
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 Total  
(n=1196) 
Outpatients  
(n=262) 
Inpatients 
(n=934) 
P value Mild*  
(n=915) 
Severe 
 (n=281) 
P value 
Demographics        
Median age (months)  
 (range) 
18.7  
(2.4-118.2) 
20.6  
(4.1-111.1) 
18.1 
 (2.4-118.2) 
0.008 17.77  
(2.4-111.1) 
21.2 
 (4.1-118.2) 
0.0001^ 
Male/female 746/450 170/92 576/358 0.345 564/351 182/99 0.361 
HCMC origin (n, %) 568 (47.5) 162 (61.8) 406 (43.5) 0.0001 448 (49.0) 120 (42.7) 0.076 
Day from onset to 
enrolment (days) 
1 (0-10) 1 (0-3) 1 (0-10) 0.167 1 (0-10) 2 (0-7) 0.0001^ 
Length of stay (days) 4 (1-31) - 4 (1-31) - 3 (1-31) 5 (1-26) 0.0001^ 
Clinical features (n, %)        
Fever 936 (78.3) 110 (42.0) 826 (88.4) 0.0001 660 (72.1) 276 (98.2) 0.0001 
Skin lesions 1034 (86.5) 234 (89.3) 800 (85.7) 0.126 777 (84.9) 257 (91.5) 0.005 
Cough 291 (24.3) 82 (31.3) 209 (22.4) 0.003 228 (24.9) 63 (22.4) 0.393 
Runny nose 237 (19.8) 78 (29.8) 159 (17.0) 0.0001 186 (20.4) 51 (18.1) 0.493 
Diarrhea 117 (9.8) 10 (3.8) 107 (11.5) 0.0001 85 (9.3) 32 (11.4) 0.308 
Drowsiness 263 (22.0) 19 (7.3) 244 (26.1) 0.0001 116 (12.7) 147 (52.3) 0.0001 
Sweating 17 (1.4) 2 (0.7) 15 (1.6) 0.391 6 (0.7) 11 (3.9) 0.0001 
Table 3.2: Baseline characteristics of the enrolled patients  
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Vomiting 525 (43.9) 61 (23.3) 464 (49.7) 0.0001 349 (38.1) 176 (62.6) 0.0001 
Irritability 357 (29.8) 12 (4.6) 345 (36.9) 0.0001 184 (20.1) 173 (61.6) 0.0001 
Myoclonus 568 (47.5) 0 568 (60.8) 0.0001 323 (36.0) 245 (87.2) 0.0001 
Lethargy 27 (2.3) 3 (1.1) 24 (2.6) 0.239 7 (0.8) 20 (7.1) 0.0001 
Tremor 111 (9.3) 2 (0.8) 109 (11.7) 0.0001 9 (1.0) 102 (36.3) 0.0001 
Ataxia 3 (0.3) 0 3 (0.3) ND 0 3 (1.1) 0.042 
Nystagmus 1 (0.1) 0 1 (0.1) ND 0 1 (0.4) 0.235 
Limb weakness 11 (0.9) 0 11 (1.2) ND 0 11 (3.9) 0.0001 
Hypertension 69 (5.8) 0 69 (7.4) ND 0 69 (24.6) 0.0001 
Blood tests        
WBC (1000 cells/mm
3
) 12.3 (2.5-76.0) 11.3 (5.6-26.9) 12.6 (2.5-76.0) 0.001 12.2 (3.9-64) 12.4 (2.5-76.0) 0.559^ 
Platelet (1000 
cells/mm
3
) 
321 (29-849) 325 (29-741) 321 (31-849) 0.421 314 (29-788) 347 (38-849) 0.0001^ 
Blood glucose (mg/L) 101 (42-223) 121 (42-212) 96 (42-223) 0.0001 102 (42-223) 98 (42-176) 0.028^ 
CRP (mg/L) 9.8 (0-620) 7.8 (0-79) 11.0 (0-620) 0.025 12.0 (0-620) 3.6 (0-87.5) 0.0001^ 
Highest grade (n, %)        
1 251 (21.0) 249 (95.0) 2 (0.2) 0.0001 257 (27.8) NA NA 
2A 664 (55.5) 13 (5.0) 651 (69.7) 0.0001 668 (72.2) NA NA 
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Note to Table 3.2: *Grade 1 and 2A; ND: not done; (^): Mann- Whitney U test 
 
#
Limb weakness and squint-eyed (n=2), limb weakness (n=5), “slow communication” (n=1), cranial nerve VII paralysis (n=1), 
unconsciousness (n=1), Guillain Barre syndrome (n=1), prolonged fever and paralyzed diaphragm (n=1), severe anemia (n=2) and 
subacute encephalitis (n=1). 
2B1 71 (5.9) NA 71 (7.6) 0.0001 NA 71 (25.3) NA 
2B2 68 (5.7) NA 68 (7.3) 0.0001 NA 68 (24.2) NA 
3 136 (11.4) NA 136 (14.6) 0.0001 NA 136 (48.4) NA 
4 6 (0.5) NA 6 (0.6) 0.349 NA 6 (2.1) NA 
Treatment (n, %)        
Milrinon 69 (5.8) 0 69 (7.4) ND 0 69 (5.8) 0.0001 
Magnesium sulfate 1 (0.1) 0 1 (0.1) ND 0 1 (0.4) ND 
IVIg 215 (18.0) 0 215 (23.0) ND 0 215 (76.5) 0.0001 
Outcome (n, %)        
Full recovery 1181 (98.7) 262 (100) 919 (98.4) 0.052 913 (99.8) 268 (95.4) 0.0001 
Recovery with 
complication or 
underlying diseases# 
12 (1.0) 0 12 (1.3) 0.08 2 (0.2) 10 (3.6) 0.0001 
Death 3 (0.25) 0 3 (0.3) 1 0 3 (1.1) 0.013 
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Of 1196 patients enrolled in the study, there were a total of 262 outpatients 
(21.9%) and 934 inpatients (78.1%). There were considerable differences in 
demographics, clinical presentation and results of blood biochemistry parameters 
between out- and inpatients. Notably, inpatients were younger than outpatients and 
were more likely to come from other provinces. Inpatients had a slightly higher 
while blood cell count and C reactive protein, but a lower level of blood glucose 
(Table 3.2).  
Compared with mild patients (Grade 1 or 2A), severe patients (Grade 2B1 or 
above) were admitted to the hospital later. Additionally, severe patients were 
slightly older, had a higher platelet count, but a lower level blood glucose and C 
reactive protein level than those with mild disease. However, the differences 
between out-and inpatients as well as between mild and severe patients in clinical 
presentations merely reflect the differences in clinical criteria utilized to classify 
HFMD grades. 
3.3.2 Results of enteroviral investigation: an overview 
Evidence of enterovirus was identified in 977 (81.6%) of 1196 study participants, 
including 339 EV-A71 (28.3%) and 638 non-EV-A71 enteroviruses (53.3%). Of 
the 339 EV-A71 positive cases, subgenogroup determination was successful in 
124 (36.5%) cases (including 52 subgenogroup B5 and 72 subgenogroup C4). Of 
the non-EV-A71 enterovirus positive cases, sequencing of VP1 fragment was 
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successful in 494/638 (77.4%), which consisted of 18 different enterovirus 
serotypes, with CV-A6, CV-A10 and CV-A16 being the major serotypes (Figure 
3.2). The frequencies of the remaining 15 enterovirus serotypes are presented in 
Table 3.3.  
Table 3.3: Frequency of other enterovirus serotypes detected in HFMD cases 
enrolled in the clinical study 
Enterovirus 
serotypes 
All  Inpatient Outpatient Severe 
patient 
Mild  
patient 
Coxsackievirus A8 22 18 4 0 22 
Coxsackievirus A2 12 12 0 2 10 
Coxsackievirus A4 8 7 1 0 8 
Coxsackievirus A5 7 7 0 0 6 
Coxsackievirus A1 2 2 0 2 0 
Coxsackievirus B1 1 1 0 0 1 
Coxsackievirus B2 1 1 0 0 1 
Coxsackievirus B3 1 1 0 0 1 
Coxsackievirus B4 1 0 1 0 1 
Echovirus 18 0 4 0 0 4 
Echovirus 5 0 3 0 1 2 
Echovirus 6 0 0 1 0 1 
Echovirus 9 0 1 0 0 1 
Poliovirus 2 0 1 0 0 1 
Rhinovirus A 0 1 0 0 1 
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Figure 3.2: Pie charts showing the detection rates of enterovirus serotypes in all HFMD patients enrolled in the study 
and groups of patient with severe and mild HFMD, and in- and outpatients. 
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3.3.3 The frequency of enterovirus serotypes detected in outpatients and 
inpatients  
The overall PCR diagnosis yield of the inpatient group was lower than that of the 
outpatient group. Likewise, there were some differences in the frequency of the 
four predominant enterovirus serotypes detected in these two groups, with EV-
A71 being the major viruses detected in the inpatient group, followed by CV-A6, 
CV-A10 and CV-A16. In contrast with the inpatient group, CV-A6 and CV-A16 
were the two leading viruses detected at comparable frequencies in the outpatient 
group, followed by EV-A71 and CV-A10 (Figure 3.2).  
3.3.4 The frequency of enterovirus serotypes detected in patients with mild 
and severe HFMD  
There were considerable differences in the overall diagnostic yield and the 
detection rates of predominant enterovirus serotypes (EV-A71, CV-A6, CV-A10 
and CV-A16) between patients with severe and mild HFMD (Figure 3.1). More 
specifically, of the 281 patients presenting with severe HFMD, EV-A71 was the 
virus detected in 64.2% of the patients, followed by sporadic detections of CV-A6 
(5.7%), CV-A16 (4.5%) and CV-A10 (1.9%) and other serotypes (1.9%)(Figure 
3.2 and Table 3.3). Meanwhile, of the 915 patients with mild HFMD, the 
detections were comparable between EV-A71 (18%) and CV-A6 (19.7%), 
followed by CV-A16 (13.6%) and CV-A10 (9.7%). The frequency of the 
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remaining serotypes detected in out/inpatients and patients with mild/severe 
HFMD are presented in Table 3.3.  
3.3.5 Associated demographics, clinical and outcome of predominant 
enterovirus serotypes 
Detailed comparisons between patients positive for predominant enterovirus 
serotypes (EV-A71, CV-A6, CV-A10 and CV-A16) are presented in Table 3.4. 
Generally, there were remarkable similarities between patients infected with CV-
A6, CV-A10 and CV-A16, while the clinical signs/symptoms as myoclonous, 
tremor, hypertension, vomiting and irritability, reflecting the characteristics of 
severe HFMD, were more often observed in EV-A71 infected patients. Likewise, 
unfavorable outcomes, especially death, were almost exclusively recorded in 
patients with EV-A71 infections. Other notable differences included age, the 
frequency of skin lesions, and blood biochemistry results. More specifically, 
patients with CV-A6 and CV-A10 infection were younger than those infected with 
EV-A71 and CV-A16. Skin lesions were recorded in only 61.1% (58/95) of CV-
A10 positive patients, but in almost all (>91%) EV-A71/CV-A6/CV-A16 infected 
patients. Patients with CV-A10 and CV-A6 infection had a higher level of C 
reactive protein and a slightly lower level of platelet count than EV-A71/CV-A16 
infected patients.  
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 EV-A71 (n=340) CV-A6 (n=196) CV-A10 (n=95) CV-A16 (n=137) P value 
Demographics      
Median age (months) 
 (range) 
22.07  
(4.2-118.2) 
15.5  
(4.4-55.4) 
15.23 
 (2.4-77.2) 
20.7  
(9.0-106.1) 
0.0001(*) 
Sex (male/female) 215 /125 142/54 55/40 80/57 0.107 
HCMC origin (n, %) 158 (46.5) 91 (46.4) 52/43 73/64 0.023 
Day from onset to 
enrolment 
2 (0-7) 1 (0-10) 1 (0-5) 1 (0-5) 0.0001* 
Length of stay (days) 4 (1-26) 3 (1-31) 3 (1-8) 3 (1-12) 0.0001* 
Clinical features (n, %)      
Skin lesions 324 (95.3) 182 (92.9) 57 (60.0) 132 (96.4) 0.0001 
Mouth ulcers 295 (86.8) 172 (87.8) 94 (98.9) 131 (95.6) 0.0001 
Fever 304 (89.4) 136 (69.4) 75 (78.9) 78 (56.9) 0.0001 
Cough 76 (22.4) 39 (19.9) 26 (27.4) 31 (22.6) 0.560 
Runny nose 54 (15.9) 32 (16.3) 22 (23.2) 36 (26.3) 0.032 
Diarrhea 25 (7.4) 10 (5.1) 11 (11.6) 11 (8.0) 0.263 
Drowsiness 143 (42.1) 22 (11.2) 9 (9.5) 8 (5.8) 0.0001 
Sweating 8 (2.4) 4 (2.0) 1 (1.1) 2 (1.5) 0.833 
Table 3.4: Characteristics of HFMD patients positive for predominant pathogens 
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Vomiting 175 (51.5) 85 (43.4) 30 (31.6) 43 (31.4) 0.0001 
Irritability 164 (48.2) 38 (19.4) 11 (11.6) 24 (17.5) 0.0001 
Myoclonus 233 (68.5) 64 (32.7) 33 (34.7) 38 (27.7) 0.0001 
Lethargy 17 (5.0) 2 (1.0) 2 (2.1) 1 (0.7) 0.015 
Tremor 88 (25.9) 6 (3.1) 3 (3.2) 1 (0.7) 0.0001 
Ataxia 3 (0.9) 1 (0.5) 0 0 0.557 
Nystagmus 1 (0.3) 0 0 0 0.739 
Limb weakness 5 (1.5) 1 (0.5) 0 1 (0.7) 0.484 
Hypertension 47 (13.8) 5 (2.6) 1 (1.1) 2 (1.5) 0.0001 
Blood tests      
WBC (x1000 cells/mm
3
) 12.5 (3.2-31.8) 12.9 (4.2-76.0) 14.55 (5.0-34.7) 11.6 (2.5-45.5) 0.0001* 
Platelet (x1000 
cells/mm
3
) 
350.5 (29-844) 324 (35-849) 308.5 (68-590) 324 (74-741) 0.0001* 
Blood glucose (mg/L) 100 (42-198) 102 (42-174) 96 (48-212) 104.5 (42-195) 0.596* 
CRP (mg/L) 3.25 (0-74) 19.9 (1.0-620) 25.1 (1.0-187.0) 8 (0.4-79.8) 0.0001* 
Highest grade (n, %)      
1 50 (14.7) 55 (28.1) 14 (14.7) 63 (46.0) 0.0001 
2 113 (33.2) 125 (63.8) 76 (80.0) 60 (43.8) 0.0001 
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2B1 32 (9.4) 5 (2.6) 3 (3.2) 8 (5.8) 0.007 
2B2 50 (14.7) 4 (2.0) 0 1 (0.7) 0.0001 
3 89 (26.2) 7 (3.6) 2 (2.1) 5 (3.6) 0.0001 
4 6 (1.8) 0 0 0 0.055 
Treatments (n, %)      
Milrinon 49 (14.4) 4 (2.0) 1 (1.1) 2 (1.5) 0.0001 
Magnesium sulfate 1 (0.3) 0 0 0 0.285 
IVIg 135 (15.6) 10 (5.1) 2 (2.1) 6 (4.4) 0.0001 
Outcome (n, %)      
Full recovery 331 (97.4) 195 (99.5) 95 (100) 135 (98.5) 0.137 
Recovery with 
complication 
7 (2.1) 1 (0.5) 0 2 (1.5) 0.290 
 
Note to Table 3.4: *Kruskal-Wallis test 
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3.3.6 Temporal distribution of predominant enterovirus serotypes  
Temporally, there were remarkable fluctuations in the detection rates of 
predominant enterovirus serotypes (EV-A71, CV-A6, CV-A10 and CV-A16) over 
the study period. Generally, EV-A71 activity was consistently high during the 
second half of the years, while CV-A6, CV-A10 and CV-A16 predominantly 
circulated in the first half of the years (Figure 3.3). Of particular note also was the 
almost absence of EV-A71 during 2017 and the first half of 2018 followed by its 
emergence in late 2018.  
3.3.7 Temporal distribution of EV-A71 subgenogroup C4 and B5 and 
phenotypic comparison between them 
Together with the previous phase of the study [133,134,139], information about 
EV-A71 subgenogroups was available in a total of 273 patients (including 190 
subgenogroup B5 and 83 subgenogroup C4). Temporally, these two 
subgenogroups replaced each other over six years in southern Vietnam. 
Specifically, from July 2013 to December 2016, B5 was dominant. After a period 
of low EV-A71 activity in 2017 and early 2018, C4 became the major virus 
detected between July and October 2018, followed by co-circulation of C4 and B5 
during the last two months of 2018 (Figure 3.4). 
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In terms of phenotype, patients infected with subgenogroup C4 were more likely 
to have severe HFMD than those infected with subgenogroup B5. The results were 
consistent for the whole study period (i.e. during 2013 and 2018), (Table 3.5).  
 Table 3.5: Phenotypic comparison between EV-A71 subgenogroup C4 and 
subgenogroup B5 
 
Note to Table 3.5: mild: grade 1 or 2A, severe: grade 2B1 or above, *comparison 
between mild and severe groups 
 
 
  2013 – 2017 2018 Total (2013 – 2018) 
  C4 
(n=17) 
B5 
(n=164) 
C4 
(n=66) 
B5 
(n=26) 
C4 
(n=83) 
B5 
(n=190) 
Mild, n% 5 (29) 139 (85) 15 (23) 12 (46) 20 (24) 151 (79) 
Severe, n% 12 (71) 25 (15) 51 (77) 14 (54) 63 (76) 39 (21) 
2B1 4 12 4 1 8 13 
2B2 3 9 12 4 15 13 
3 5 4 32 9 37 13 
4 0 0 3 0 3 0 
P value* <0.001 0.04 <0.001 
OR (95%CI) 13 (3.9 – 51.5) 2.9 (0.99 – 8.5) 12.1 (6.3 – 23.7) 
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Figure 3.3: Temporal distribution of four major enterovirus serotypes during the study period and the period from 
July 2013 to July 2015.  
Note: The Y-axis shows the number of cases. The synthesized data also covers the period from July-2013 to July 2015 
which was previously reported.  
0	
20	
40	
60	
80	
100	
120	
140	
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Ju
l-
13
 
S
ep
-1
3 
N
ov
-1
3 
Ja
n-
14
 
M
ar
-1
4 
M
ay
-1
4 
Ju
l-
14
 
S
ep
-1
4 
N
ov
-1
4 
Ja
n-
15
 
M
ar
-1
5 
M
ay
-1
5 
Ju
l-
15
 
S
ep
-1
5 
N
ov
-1
5 
Ja
n-
16
 
M
ar
-1
6 
M
ay
-1
6 
Ju
l-
16
 
S
ep
-1
6 
N
ov
-1
6 
Ja
n-
17
 
M
ar
-1
7 
M
ay
-1
7 
Ju
l-
17
 
S
ep
-1
7 
N
ov
-1
7 
Ja
n-
18
 
M
ar
-1
8 
M
ay
-1
8 
Ju
l-
18
 
S
ep
-1
8 
N
ov
-1
8 
CV-A10 
CV-A16 
CV-A6 
EV-A71 
Total cases 
88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Reconstructed temporal distribution of EV-A71 subgenogroup C4 and B5 during 2013 – 2018.  
Note: The left Y-axis shows the number of subgenogroup C4/B5 cases. The right Y-axis shows the number of EV-A71 
cases. Data were synthesized for the period during July 2015 and December 2018 which was also derived from our previous 
reports for the period from July 2013 to July 2015 [134]. 
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3.4 Discussion 
Here I report the results of clinical, etiological and epidemiological investigations 
of patients presenting with clinically suspected HFMD, who were admitted to or 
sought for medical treatment at outpatient departments at the major hospitals in Ho 
Chi Minh City Vietnam, where the majority of HFMD cases in Vietnam has been 
reported to date. Together with previous reports from Vietnam [134,135], the data 
have thus provided significant insights into important aspects of this emerging 
infection over six years (2013 – 2018). More specifically, I have demonstrated the 
emergence CV-A6 as a major cause of HFMD in Vietnam, consistent with the 
situation worldwide [76,140], and the temporal replacement between main causes 
of HFMD over time, hugely important for vaccine development and 
implementation. Yet, despite the emergence of CV-A6 and to some extend CV-
A10, EV-A71 remains the leading cause of severe HFMD in Vietnam and that 
EV-A71 activity was high in the second part of the calendar years during the study 
period. Additionally, adding to the existing data about dominance of EV-A71 
subgenogroup C4 in Vietnam between July and October 2018, for which I led the 
investigation as the outbreak occurred [135], was the co-circulation of C4 and B5 
during the last two months of the 2018 outbreak.  
The underlying mechanism determining the temporal replacement between 
predominant HFMD pathogens throughout the year in Vietnam, as well as the 
emergence/disappearance of specific EV-A71 subgenogroup remain to be 
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determined [21,134]. Notably, in contrast to the continuous circulation of EV-A71 
during the first two years of the study (2013- 2015) [134], results of the present 
study show that the emergence of EV-A71 during the second half 2018 was 
preceded by the low detection rate of EV-A71 in HFMD cases enrolled in the 
clinical study during 2017 and the first half of 2018, suggesting that EV-A71 
endemicity in Vietnam was low during this period, which may have resulted in the 
accumulation of a sufficient number of susceptible young children leading to the 
emergence of EV-A71 in late 2018 [135,141]. Collectively, the data point out that 
active surveillance for pathogen circulation, especially viruses that are known to 
cause severe outbreaks, e.g. EV-A71, remains essential to inform the local public 
health authorities in response to HFMD outbreaks and the development of 
appropriate/effective HFMD vaccines.  
My data has demonstrated that, compared with subgenogroup B5, C4 was more 
likely to cause severe HFMD, suggesting that they may be different in 
pathogenicity. This finding is consistent with a recent study conducted in northern 
parts of Vietnam between 2015 and 2016 [142]. In this study, Chu S.T. et al 
suggested that EV-A71 subgenogroup C4 might be more neuro-virulent than 
subgenogroup B5 based on mouse models and the proportion of hospitalized 
cases. However, the number of EV-A71 subgenogroup C4 in this study was 
significantly lower than in my study (10 vs 83) and 90% (38/40) of inpatients in 
this study had a clinical diagnosis of grade 2 illness, but the number of cases with 
grade 2A, 2B1 or 2B2 was not clearly reported and therefore, it is uncertain 
91 
 
whether inpatients had severe disease, defined as grade 2B1, 2B2, grade 3 and 
grade 4 in my study. Collectively, in terms of the association between EV-A71 
subgenogroup C4 and severe HFMD, my study provided more evidence in clinical 
perspective while Chu S.T. et al proved that C4 strains of EV-A71 might cause 
severe disease in mice.  
Viruses of subgenogroups C and B, especially C4 and B5, have been 
predominantly detected in recent outbreaks in the Asia-Pacific region, including 
China, Taiwan and Vietnam, with frequent switches in predominant 
subgenogroups overtime. To this end, existing data fails to link the association 
between specific (sub)genogroups and severe HFMD. In Vietnam, historically 
subgenogroup C4 has been linked with major outbreaks during 2011–2012 [40] 
and most recently 2018 [135]. Additionally, data of the present study show that C4 
infected patients were more likely to have severe HFMD than B5 patients. As 
such, the results parallel observational data from Thailand and China, where C4 
has been responsible for major HFMD outbreaks [4,143]. In contrast, elsewhere in 
Taiwan, subgenogroup C2 and B4 were responsible for the massive outbreak 
involving 1.5 million infections and 78 death in 1998 [6], while C4 and B5 have 
both been linked with recent outbreaks [144,145]. Collectively, further research 
should address the underlying factors that determine the scales and the severity of 
HFMD in specific localities, paramount importance for development of 
intervention strategies. 
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HFMD is generally a mild infection, with severe disease occurring in only a small 
proportion of the affected patients. It remains unresolved regarding the factors 
determining the clinical consequences of the affected individuals, although EV-
A71 is often associated with severe HFMD. The observed data on the late hospital 
admission among EV-A71 infected patients and among patients presenting with 
severe HFMD suggests that the time since onset of illness to hospital admission 
may play a role.  
The overall PCR diagnostic yield of 81.6% obtained in the present study is within 
the ranges of previous reports. The higher PCR detection rate of the outpatient 
group as compared to that of the inpatient group may be attributed to the longer 
duration of illness at enrolment of the inpatients, albeit not statistically significant. 
Likewise, similar to previous reports [146,147], the results show that HFMD is 
diverse in etiology with over 19 enterovirus serotypes being linked with the 
current HFMD epidemic in Vietnam. Given the weak/lack of cross-neutralization 
between them, especially among predominant serotypes [148–151], the data thus 
point out that multivalent vaccines are needed to control this ongoing epidemic. 
Albeit arguably challenging to develop, the requirement of such multivalent 
vaccines are essential due to their potential benefit [147,151–153], and the high 
burden posed by HFMD [31,124,133]. Nevertheless, because of the high 
prevalence of EV-A71 in both mild and severe HFMD patients, EV-A71 vaccines, 
which have been successfully developed elsewhere [113,151], could potentially 
reduce the major impact of HFMD in the region where EV-A71 endemic is high. 
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The major strength of my study is that it was based at tertiary referral hospitals in 
Chi Minh City, which are responsible for receiving HFMD from southern Vietnam 
with a population of over 40 million. Nevertheless, owing the limitation of 
resource, I was not able to expand my sampling to the central and northern 
Vietnam. Therefore, the epidemic picture in these respective areas remains to be 
unlocked. Additional limitation includes the adjustment in sampling approach 
from three to one study site (CH1) in 2018. Nevertheless, given that CH1 is the 
largest tertiary center for CH1 in southern Vietnam, the results have uniquely 
reflected the ongoing epidemic patterns of HFMD in southern Vietnam over six 
years (2013 – 2018).   
3.5 Conclusion 
To summarize, the obtained results of this chapter showed a complex dynamics of 
the ongoing HFMD epidemic in Vietnam, which have in part been driven by the 
emergence of pathogens, especially EV-A71 and CV-A6. The results pointed out 
that there is an urgent need to develop multivalent vaccine in order to control this 
emerging infection and that active surveillance for pathogen circulation remains 
essential to inform the local public health authorities in development of 
appropriate intervention strategies in order to reduce the overall burden of 
unprecedented HFMD outbreaks.  
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Chapter 4 
Heart rate variability in children with hand, foot and mouth disease in 
Vietnam between 2017 and 2018 
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4.1 Background 
Whilst the vast majority of HFMD cases are mild and self-limited, approximately 
10% of admitted cases progress to severe and potentially fatal conditions including 
central nervous system involvement, autonomic nervous system (ANS) 
dysregulation and cardiopulmonary failure [8]. Early identification of those likely 
to deteriorate or with more severe diseases would be beneficial both for patient 
management and resource allocation, and methods of detecting autonomic nervous 
system activity in real-time may be valuable in enabling this. 
HRV has been investigated in many diseases associated with autonomic nervous 
system imbalance: it is predictive of poor outcome following myocardial 
infarction and in diabetes mellitus, and was recently shown to be an indicator of 
autonomic nervous system disturbance in tetanus [78,94,107,154]. It is therefore 
possible that HRV is a valuable marker of autonomic nervous system imbalance 
and therefore disease severity in HFMD. Some preliminary data in HFMD has 
been published, reporting HRV metrics in 40 Taiwanese children with HFMD, 
which indicated relative sympathetic nervous system activation. However, in this 
study indices were taken from a single 5 minute Holter-monitor recording and 
from a population with HFMD but not differentiated according to pathogen. It is 
unclear how HRV measures relate to the different causes of HFMD (ie EV-A71 vs 
non EV-A71 pathogens) and whether there are more scalable ways of obtaining 
96 
 
ECG recordings, potentially allowing real-time analysis, vital in outbreak 
situations. 
I therefore carried out the present pilot study, using wearable devices to record the 
ECG signal for up to 24 hours in a large sample of children with different 
severities of HFMD and known aetiology.  
4.2 Methods 
4.2.1 Setting and study design  
This study was prospectively conducted at CH1 during 2017–2018. Hospitalized 
patients aged 16 years old or younger, who were clinically diagnosed with HFMD 
at different severities, from grade 2a to grade 4, and had an illness day of 7 or less 
were eligible for enrollment. After informed consent was obtained, patients were 
enrolled and followed up until discharge. 
4.2.2 Inclusion and exclusion criteria:  
Inclusion criteria: Patients who met all following criteria were eligible for 
enrolment in this study: (1) child with a clinical diagnosis of HFMD grade 2A or 
above; (2) need to be monitored at the Emergency room of Infectious Disease 
Department, Children’s Hospital 1; (3) their day of illness from the onset is 7 or 
less; (4) their legal representative consented to participate in the study.  
Exclusion criterion: Any patient for whom the attending physician believed 
another diagnosis was more likely. 
4.2.3 Sample size  
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This was a pilot study and I aimed to collect at least 120 patients in order to 
include at least 30 very severe patients (Grade 3 or 4). Additionally one of the 
aims of this study was to test the feasibility of a wearable device to measure in an 
outpatient setting, thus we also wanted at least 30 cases presenting with grade 1. 
4.2.4 Data collection  
ECG signal was collected for up to 24 hours, using e-Patch (see below). 
Information about demographics, weight, body temperature, breath rate, blood 
pressure, signs/symptoms, disease grades on admission and disease grades at 
discharge were also collected using an adapted version of the CRF of our on-going 
HFMD program. Throat swabs were collected from all participants at enrolment in 
order to identify pathogens of the disease using methods described in chapter 3 
and Appendix 1. 
4.2.5 E-Patch 
The ECG signal is generated by electrical activity of the sinoatrial node which 
controls the expansion and contraction of the heart. It can be recorded using an 
ECG machine with electrodes placed at various positions on the surface of the 
chest whereas the e-Patch ECG signal is measured by a small patch firmly adhered 
to the skin of the sternum area. Each e-Patch consists of two parts: a sensor and a 
single electrode.      
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Figure 4.1: Elements and position of E-patch in patients’ chest 
The e-Patches used in this study are produced by DELTA Danish Electronics, with 
the serial number AMS3000. 
4.2.6 HRV analysis and statistical consideration 
Before HRV analysis was performed, the ECG signal was manually edited to 
exclude noise and artefacts. Recordings were divided into 5-minute windows. All 
5-minute windows with artefacts or noise were excluded. The remaining 
recordings were analysed using the sequential function of HRV analysis software 
version 1.1, produced by St. Etienne University, France dated May 2017 [84]. For 
severe and very severe patients who had to stay in the emergence room or 
intensive care unit the ECG signal was recorded for up to 24 hours and averages of 
HRV indices derived from night time windows (between 10 pm to 4 am) were 
used for analysis. For children with mild grades who were observed in other rooms 
in the Infectious Disease Department, recording durations fluctuated at around six 
hours. For these patients, means of indices from three consecutive five-minute 
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HRV windows when patients were calm (based on regularity of heart rates) were 
selected.  
The linear and non-linear HRV indices were calculated with the reference being 
standard and a re-sampling rate of 2 Hz. Linear methods include time domain and 
frequency domain analysis while non-linear approach consists of Poincare´ plot 
analysis and detrended fluctuation analysis (DFA) [83]. These HRV indices are 
clearly defined in Table 1.4 and were selected as most commonly used and those 
recommended by consensus guidelines. Additionally, as this is an initial 
exploratory analysis, by using different analytic methods we aimed to identify 
consistent trends that might indicate autonomic nervous system activity. 
Median and inter-quartile range (IQR) are given for skewed variables. Statistical 
differences in HRV indices among severities of disease and groups of detected 
pathogens were tested using the Mann-Whitney U- test with a P-value of less than 
0.05 considered as a statistically significant difference.   
4.3 Results 
4.3.1 Characteristics of hospitalized patients with HFMD  
From April 2017 to December 2018, a total of 142 hospitalised patients were 
enrolled in this study. Of these, the number of grade 2A, 2B1, 2B2, grade 3 and 
grade 4 was 40 (28.2%), 16 (11.3%), 32 (22.5%), 50 (35.2%) and 4 (2.8%), 
respectively. Demographic characteristics and clinical features at enrollment of 
142 enrolled patients were described in Table 4.1. In general, the vast majority of 
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cases (97.2%) were younger than 60 months with a median age of 21.7 (IQR: 2.4-
154.8) months. Male and HCM city origin accounted for 57.7% and 42.3%, 
respectively. Clinical features on admission are given in Table 4.1. In terms of 
clinical presentation, the proportion of high fever, lethargy, myoclonus, trembling 
and mottled skin in severe and very severe group was significantly higher than in 
the mild group. Regarding detected pathogens, the most common enterovirus 
serotype was EV-A71 (56.3% of cases), followed by CV-A16 (4.9%), CV-A10 
(4.2%) and CV-A6 (3.5%). In the severe group, the proportion of children with 
EV-A71 (64.6%) was almost double that of those in the mild group (30%). 
Conversely, CV-A6, CV-A10 and CV-A16 were more common in the mild group.   
4.3.2 Data collection from e-Patch 
E-Patch recordings were taken in all subjects. In all of these recordings, the ECG 
signal was obtained and no adverse events associated with using the wearable 
occurred. A total of 5526 epoches of 5-minute ECG recordings were available for 
analysis. Of these, the number of qualified epoches from grade 2a, 2b1, 2b2, grade 
3 and grade 4 were 120, 863, 1783, 2627 and 133, respectively. 
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Table 4.1: Baseline characteristics of patients with HFMD on admission 
Variables Mild 
 (grade 2A) 
n=40 
Severe 
(2B1&2B2) 
n=48 
Very severe 
(grade 3&4) 
n=54 
Total 
n= 142 
Demographics     
Male/female  21/19  26/22  35/19  82/60  
Median age (months) 
(range) 
16 (2.4-43.2) 25.6 (6.8-154.8) 19 (4.1-118.2) 21.7 (2.4-154.8) 
HCM city origin 
Other provinces 
18 (45) 
22 (55) 
19 (39.6) 
29 (60.4) 
23 (42.6) 
31 (57.4) 
60 (42.3) 
82 (57.7) 
Length of stay (days) 
Median (range) 
3 (2-10) 4 (2-10) 7 (1-43) 5 (1-43) 
Clinical features (n, %)     
Skin lesion  37 (92.5) 45 (93.8) 54 (100) 135 (95.1) 
Mouth ulcer  38 (95) 45 (93.8) 46 (85.2) 129 (90.8) 
High fever  25 (62.5) 36 (75) 50 (92.6) 111 (78.2) 
Cough  4 (10) 2 (4.1) 6 (11.1) 12 (8.5) 
Runny nose  13 (32.5) 1 (2.1) 3 (5.5) 17 (12) 
Vomiting  11 (27.5) 11 (22.9) 8 (14.8) 30 (21.1) 
Diarrhea  4 (10) 6 (12.5) 8 (14.8) 18 )12.7) 
Lethargy  9 (22.5) 34 (70.8) 41 (75.9) 84 (59.2) 
Irritable  35 (87.5) 39 (81.3) 38 (70.4) 111 (78.2) 
Myoclonus (history)  8 (20) 35 (72.9) 33 (61.1) 75 (52.8) 
Sweating  2 (5) 1 (2.1) 5 (9.2) 8 (5.6) 
Drowsiness  1 (2.5) 3 (6.3) 10 (18.5) 14 (9.9) 
Trembling  0 18 (37.5) 16 (29.6) 34 (23.9) 
Mottled skin  0 2 (4.1) 5 (9.2) 7 (4.9) 
Pulse (times/minute) 
Median (range) 
140 (110-168) 140 (106-187) 148 (118-190) 143.5 (106-190) 
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SBP (mmHg) 
Median (range) 
92.5 (80-110) 100 (90-160) 105 (85-160) 100 (80-160) 
DBP (mmHg) 
Median (range) 
60 (45-68) 60 (50-95) 60 (52-100) 60 (45-100) 
Respiratory rate 
(times/minute) 
Median( range) 
32 (22-60) 34 (22-46) 38 (22-70) 34 (22-70) 
Pathogens (n, %)     
- EV-A71 12 (30) 31 (64.6) 37 (68.5) 80 (56.3) 
- CV-A6 2 (5) 2 (4.3) 1 (1.8) 5 (3.5) 
- CV-A10 6 (15) 0 0 6 (4.2) 
- CV-A16 2 (5) 3 (6.4) 2 (3.6) 7 (4.9) 
- Other enterovirus 
serotypes (*) 
8 (20) 4 (8.3) 8 (14.8) 20 (14.1) 
- PCR negative 10 (25) 7 (14.6) 7 (13) 24 (16.9) 
(*): Consists of CV-A5 (1 case), CV-A8 (1 case) and not serotyped enteroviruses (18 cases) 
 
4.3.3 Distribution of HRV indices by severity of HFMD  
The distribution of HRV indices groups by disease severity is shown in Table 4.2. 
In general, the overall autonomic system activity as indicated by Total Power and 
SDNN showed was with increasing severity of HFMD between mild and more 
severe cases, although values for very severe were lower than severe.  
In terms of parasympathetic activity all indices show a consistent trend to reduced 
parasympathetic activity with increasing grades of disease (Table 4.2). The time 
domain index (RMSSD) gradually declined by disease severity, with median 
decreasing from 8.46 milliseconds (ms) in mild group, 6.45 ms in severe group to 
5.43 ms in the very severe group. A similar trend was seen in the frequency 
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domain variables, where HFnu in mild patients was 1.8 and 2.2 times higher than 
among severe and very severe patients, respectively (p = 0.0001). SD1 and SD1nu 
also gradually declined by severity of the disease, with the highest value being 
observed in mild patients, followed by severe and then very severe ones.  
Indices indicative of mixed parasympathetic and sympathetic activity however 
showed the opposite pattern, with a trend towards increased values in more severe 
grades of disease. Low frequency (LF), normalized low frequency (LFnu) and 
LF/HF ratio of severe and very severe group were significantly higher than in the 
mild group (p= 0.0001). Poincaré-derived variables of SD2 and SD2nu, were 
significantly higher among mild patients than in the severe and very severe group 
(P=0.044 and P=0.017, respectively). Indices reflecting relative high and low 
frequency activity of IMA1, IMA2, LF:HF and SD1:SD2 showed increase in 
lower frequency ranges, indicative of relative increase in sympathetic activity. 
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Table 4.2: Heart rate variability indices in children with HFMD by severity  
HRV indices 
Median (IQR) 
 
Mild  
Grade 2a  
(n=40) 
Severe 
Grade 2b1/2b2  
(n=48) 
Very severe 
Grade 3/4  
(n=53) 
P1  
 (*) 
 
P2 
(*) 
 
P3 
(*) 
 
Heart rate 
(beats/minute) 
125.53 (117.76-143.42) 137.23 (124.25-142.99) 137.88 (127.61-147.56) 0.159 0.011 0.256 
SDNN (ms) 12.37 (9.50-20.97) 16.82 (12.78-21.84) 14.38 (9.31-21.77) 0.059 0.571 0.262 
RMSSD (ms) 8.46 (4.93-12.88) 6.45 (4.69-9.25) 5.43 (4.72-8.61) 0.248 0.026 0.314 
Ptot (ms
2
) 128.00 (72.20-351.28) 256.38 (142.97-486.49) 189.13 (76.34-445.02) 0.019 0.288 0.199 
VLF (ms
2
) 71.78 (30.44-188.96) 158.97 (99.91-306.12) 116.27 (41.11-266.51)  0.002 0.091 0.083 
LF ((ms
2
)) 29.76 (15.17-63.80) 48.41 (25.59-104.53) 42.53 (18.37-113.15) 0.009 0.088 0.572 
HF ((ms
2
)) 6.38 (2.96-24.60) 6.35 (2.60-18.01) 3.59 (1.78-11.89) 0.814 0.049 0.081 
LFnu (%) 48.28 (37.70-60.27) 63.76 (53.11-69.30) 64.38 (54.72-78.65) 0.0001 0.0001 0.399 
HFnu (%) 13.30 (9.09-19.79) 7.35 (5.73-11.82) 6.02 (4.30-8.71) 0.0001 0.0001 0.009 
LF/HF 3.85 (2.56-6.15) 11.31 (5.86-15.66) 12.56 (9.09-18.58) 0.0001 0.0001 0.088 
SD1 (ms) 5.99 (3.49-9.11) 4.51 (3.31-6.54) 3.73 (3.33-6.09) 0.209 0.025 0.373 
SD2 (ms) 15.75 (12.33-27.51) 22.53 (16.90-29.95) 19.95 (12.74-29.52) 0.044 0.344 0.331 
SD1/SD2 0.34 (0.27-0.49) 0.25 (0.20-0.32) 0.24 (0.18-0.31) 0.0001 0.0001 0.550 
SD1nu (%) 1.24 (0.89-1.83) 1.04 (0.76-1.37) 0.94 (0.79-1.33) 0.147 0.038 0.629 
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SD2nu (%) 3.71 (2.56-5.57) 4.97 (3.90-6.06) 5.04 (3.06-6.46) 0.017 0.103 0.591 
pLF1 (ms
2
) 19.72 (9.28-42.84) 34.80 (18.53-60.27) 26.98 (12.21-63.15) 0.013 0.185 0.327 
pLF2 (ms
2
) 30.35 (13.22-60.48) 55.02 (31.91-101.74) 43.40 (15.32-87.65)  0.002 0.192 0.146 
pHF1 (ms
2
) 11.09 (4.66-19.18) 13.45 (8.61-29.69) 8.24 (4.10-22.73) 0.131 0.571 0.031 
pHF2 (ms
2
) 16.44 (3.80-75.44) 10.86 (3.55-32.13) 6.32 (2.90-24.15) 0.412 0.063 0.231 
IMAI1 0.79 (0.38-1.30) 1.94 (1.11-2.37 1.53 (1.13-2.53) 0.0001 0.0001 0.739 
IMAI2 1.08 (0.58-2.13) 3.22 (1.70-4.32) 2.49 (1.52- 4.49) 0.0001 0.0001 0.454 
(*) Mann-Whitney U test; P1: Mild vs Severe; P2: Mild vs Very Severe; P3: Severe vs Very Severe
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3.2 Distribution of HRV indices by pathogens  
Table 4.3 depicts the distribution of HRV indices by detected pathogens (EV-A71 
and non EV-A71). In general, HRV indices for patients with HFMD caused by 
EV-A71 were lower than those caused by other pathogens. Compared to patients 
with non EV-A71 pathogens, patients with EV-A71 associated HFMD had 
increased HRV indices associated with sympathetic activity and decreased HRV 
indices associated with parasympathetic activity. When markers of autonomic 
balance were specifically looked at those with EV-A71 had a significantly higher 
LF/HF ratio, IMAI1 and IMAI2 than those with non EV-A71 HFMD, indicating 
relative activation of the sympathetic nervous system compared to 
parasympathetic nervous system. The SD1:SD2 ratio was also non-significantly 
reduced (also indicating relative parasympathetic activation to sympathetic 
activation).  
Table 4.3: Heart rate variability indices in children with HFMD by pathogen 
HRV indices 
 
EV-A71 (n=80) 
Median (IQR) 
Non-EV-A71 (n=38) 
Median (IQR) 
P-value 
 
Heart rate 
(times/minute)  
137.88 (128.01 - 144.59) 130.08 (118.91 - 145.99) 0.188 
SDNN (ms) 14.38 (9.24 - 21.29) 17.38 (12.64 - 23.51) 0.070 
RMSSD (ms) 5.72 (4.67 - 8.50) 8.77 (5.26 - 13.76) 0.001 
Ptot (ms
2
) 194.57 (85.99 - 476.32) 286.15 (122.62 - 544.19) 0.186 
VLF (ms
2
) 116.27 (44.11 - 313.64) 147.89 (52.52 - 260.00) 0.609 
LF (ms
2
) 40.71 (19.29 - 86.86)  59.11 (28.87 - 115.62) 0.103 
HF (ms
2
) 4.31 (1.74 - 10.89) 12.31 (2.75 - 21.49) 0.004 
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LFnu (%) 64.32 (54.10 - 69.36) 55.03 (42.79 - 64.86) 0.008 
HFnu (%) 7.17 (5.54 - 9.71) 11.62 (5.60 - 17.65) 0.012 
LF/HF 10.67 (7.57 - 15.08) 5.00 (2.79 - 13.89) 0.001 
SD1 (ms) 4.02 (3.22 - 5.98) 6.20 (3.71 - 9.74) 0.001 
SD2 (ms) 19.95 (12.59 - 27.82) 23.32 (16.22 - 31.90) 0.090 
SD1/SD2 0.25 (0.20 - 0.32) 0.31 (0.21 - 0.44) 0.130 
SD1nu (%) 0.93 (0.76 - 1.26) 1.32 (0.98 - 1.90) 0.001 
SD2nu (%) 4.55 (2.98 - 5.81) 5.23 (3.85 - 6.46) 0.122 
pLF1 (ms
2
) 26.36 (12.21 - 53.78) 37.17 (17.00 - 66.91) 0.157 
pLF2 (ms
2
) 46.31 (17.89 - 83.50) 49.13 (22.27 - 92.81) 0.492 
pHF1 (ms
2
) 9.76 (5.02 - 20.22) 18.98 (8.60 - 36.34) 0.015 
pHF2 (ms
2
) 6.32 (2.95 - 21.71) 23.97 (4.05 - 83.42) 0.002 
IMAI1 1.83 (1.07 - 2.39) 0.80 (0.53 - 1.54) 0.0001 
IMAI2  3.19 (1.63 - 4.42) 1.17 (0.63 - 2.26) 0.0001 
 
Figures 4.2-5 show HRV indices according to both disease severity and pathogen. 
Again, consistent patterns can be seen in terms of HRV indices. Patients with EV-
A71 associated HFMD have consistently lower HRV indices at every severity 
grade than other patients with HFMD. In terms of parasympathetic-related indices, 
most clear are HF and HFnu, the most commonly cited indicators of 
parasympathetic activity, and they show a clear decrease with increasing severity 
of disease for both EV-A71 and non EV-A71 cases. Similarly for HRV indices 
associated with sympathetic activity, patients with EV-A71 HFMD have 
consistently lower HRV variables at each disease severity level, but both groups of 
108 
 
patient show a trend to higher sympathetic activation. This is further reflected in 
LF/HF and SD1/SD2 ratios and IMA1 and IMA2 values. 
  
  
Figure 4.2: Distribution of HRV indices reflecting the general activity 
of ANS by pathogens in different severities 
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Figure 4.3: Distribution of HRV indices reflecting parasympathetic 
activity by pathogens in different severities  
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Figure 4.4: Distribution of HRV indices reflecting sympathetic activity 
by pathogens in different severities 
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Figure 4.5: Distribution of HRV indices reflecting the autonomic 
imbalance by pathogens in different severities 
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4.4 Discussion 
This study was designed as a pilot study to explore HRV indices in children with 
HFMD of known aetiology and to investigate whether HRV might be of value in 
severity prediction in HFMD. This is the first study providing a wide range of 
HRV indices in hospitalized children with HFMD and the largest reported series 
of HRV data in HFMD.  
My study was also a pilot study to establish the feasibility of using a wearable 
device to accurately record ECG signal (and hence HRV) in young children with 
different degrees of disease severity. As such, I have established the feasibility of 
this method, which may therefore be suitable for a monitoring large numbers of 
children, for example in outbreak situations. 
In general, the values of these HRV indices were significantly lower than in 
normal range of healthy children [82]. Studies in other diseases have indicated 
reduced HRV with increasing disease severity and poor outcome [154]. A 
previous study in Taiwanese children with HFMD also showed similar findings of 
reduced HRV parameters with increasing disease severity [104]. Mechanisms for 
this overall reduction in HRV are likely to be complex but several theories have 
been proposed to explain the reduced HRV in cardiovascular disease. Principal 
theories include a reduction in vagal tone, ‘uncoupling’ of regulatory mechanisms 
and changes in sino-atrial node responsiveness. It should also be noted that 
reduced power of HRV represents reduced fluctuation within the autonomic 
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nervous system and therefore may occur due to lowering of autonomic input or, 
conversely, a ceiling effect with high sympathetic input. 
HRV indices in this study were generally lower than those reported in the study in 
children with HFMD in Taiwan. There are many possible reasons for this, 
however, the Taiwanese study used a single recording only which may have 
introduced bias, in this study noisy recordings with movement artefacts (which 
falsely increase the HRV indices measured) were removed. Children in the 
Taiwanese study were also older, which may be associated with increased HRV. 
Other reasons include differences in sample size and other treatments 
administered. 
It is also however possible that there are technical reasons for this difference. 
Firstly, it is possible that we obtained different results as we recorded the ECG 
signal by a different device to the standard Holter monitor used in most other 
studies. The present study used e-Patch with one electrode while [82] used a 
Holter monitor with several electrodes. With more leads, Holter monitors were 
more likely to capture heart beat signal at higher power compared to a single 
electrode-cardiac wearable device. Nevertheless, the main measure here is R-R 
interval from which all the indices in this chapter are described and it is unlikely 
that such a significant difference occurs in measuring this. An alternative 
explanation is that the present study minimized effect of noise and artifacts on 
HRV features (i.e. improving the signal quality) allowing more accurate 
measurement. It was noted that much higher variability was detected 
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(inaccurately) when noise or movement artefacts were present. By excluding this 
before analysis we have removed this as a source of error in variability 
measurements [82].   
4.4.1 HRV indices and severity of HFMD 
The interplay between parasympathetic and sympathetic nervous systems in 
control of heart rate is highly complex and a simple interpretation of a reciprocal 
relationship between the two is insufficient. Nevertheless, in order to understand 
the pathophysiology of HFMD, a relatively simple interpretation may be helpful. 
In my study, the relationship between HRV indicators of overall autonomic 
modulation and pathogen and disease severity is not clear, however, the complex 
nature of HRV modulation and confounding factors, such as medication, diurnal 
rhythm and position, are possible explanations. My data, however, does show 
much more clear relationships between indicators associated with sympathetic or 
parasympathetic nervous system modulation and both disease severity and 
pathogen.  
Consistent trends in HRV in both time frequency and Poincaré domains are seen, 
implying autonomic imbalance varying with disease severity. Moreover, HRV 
indices could be considered as potential factors/indicators in classifying the 
severity of HFMD alongside existing clinical signs and symptoms.  
A novel and important finding in this study is that consistently lower HRV metrics 
are seen in patients with EV-A71 associated HFMD, at each level of disease 
severity, compared to those with non EV-A71 associated disease. This finding is 
115 
 
novel and supports the view that EV-A71 associated HFMD disease is different to 
that caused by other enteroviruses. It is known that there are differences in clinical 
features depending on aetiology, and that EV-A71 associated disease is often more 
severe. Mortality rates in EV-A71 associated disease are increased compared to 
non EV-A71 disease and our study suggests that this may be due to fundamental 
differences in cardiopulmonary or neural pathophysiology. One possible 
hypothesis is that EV-A71 disease is associated with a different inflammatory 
phenotype than non EV-A71 disease. Observational studies in cardiovascular 
disease have shown a relationship between HRV and inflammatory markers with 
reduced HRV associated with increased pro-inflammatory markers of C-reactive 
protein (CRP), interleukin-1, interleukin-6 and tumour necrosis factor alpha. 
Inflammatory markers were not measured in this study, but existing data reports 
EV-A71 associated disease to be associated with lower CRP than other causes of 
HFMD [134,135]. 
An alternative explanation is that EV-A71 HFMD results in different central 
nervous system pathology. EV-A71 associated HFMD is associated with MRI 
hyperintense signals in the medulla, pons and midbrain, with the pontine 
tegmentum being the commonest lesion. As this region contains sympathetic 
neural projections, it has been suggested that lesions here are central in 
pathophysiology of complications of severe HFMD. There are few published data 
concerning MRI findings in non-EV-A71 HFMD [155,156], but it is possible that 
these are different, hence differential effect on the nervous system. 
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4.4.2 Limitation of the study 
To my best knowledge, this is the first time e-Patch was used to record ECG signal 
in children with HFMD for at least six hours. However, the quality of ECG signal 
was not so good for whole recording duration because it was hard to keep sick 
young children calm for hours, especially in mild patients. The movement of 
patients may increase their heart rates, affecting HRV indices, although short-term 
HRV indices produced from the ECG signal recording at rest or sleep were used to 
minimize that affect. A further significant limitation is that more severe patients 
received more sedative drugs and were less mobile, which may have also affected 
HRV. A larger study or a more complex modeling approach may be able to 
address this issue. 
4.5 Conclusion  
My data reveals that children with EV-A71 infection were more likely to have 
ANS imbalance and HRV indices may have a potential application in 
differentiating disease severity and early detection of disease progression. Modern 
machine learning techniques may allow more in-depth analysis of ECG signal and 
more accurate classification and prediction of disease severity. Moreover, 
algorithms extracted from models could be utilized to create an app which may be 
installed in smart phones or other devices for clinical use in future. 
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Chapter 5 
Economic burden attributed to children presenting to hospitals with 
hand, foot and mouth disease in Vietnam 
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5.1 Background              
In view of recent advances in HFMD vaccine development and the success of EV-
A71 vaccine research as well as its potential benefit [157], it is anticipated that 
HFMD vaccines, will be widely implemented in the near future. Therefore, 
knowledge about the economic burden of HFMD in Vietnam is essential to inform 
local policy makers in planning and prioritizing resources for vaccine development 
and implementation, and outbreak response. However, such data are currently 
unavailable for Vietnam. Here, I report the results of a prospective descriptive 
hospital-based study aiming at estimating costs attributed to HFMD for all clinical 
severities, specific pathogens and geographic locations in Vietnam.  
5.2 Methods               
5.2.1 Study design and Settings 
The present study was conducted at Children’s Hospital 1 (CH1), CH2 and 
Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, Vietnam during April 
2016–December 2017. Direct and indirect costs have been collected from patients 
with HFMD participating in an ongoing prospective observational HFMD study. 
Regarding estimation of indirect costs, I excluded productivity losses due to 
premature deaths [117].   
5.2.2 Patient enrollment and data collection  
Patient enrollment was carried out at the aforementioned hospitals during April 
2016–December 2017. I screened any patient ≤16 years of age presenting to 
outpatient departments or admitted to inpatient wards of CH1, CH2 or HTD with a 
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clinical diagnosis of HFMD and, if outpatients, an illness day of ≤3 days for 
enrolment in our study.  
Information regarding demographic, clinical signs or symptoms, clinical grades of 
the disease, treatments, laboratory tests, length of hospital stay, disease outcomes, 
and associated economic costs from the participants was collected from each study 
participant. For enterovirus serotype determination, acute throat and rectal swabs 
were also collected at enrolment.  
Information about associated economic burden was captured through hospital 
invoices and face-to-face interview of the accompanying relatives. The former 
included information about hospital fees attributed to hospitalization including 
both costs covered by health insurance and patients’ relative out-of-pocket 
payments. The remaining information was collected for the period before hospital 
admission, during hospitalization and 7 days after discharge, including costs 
associated with medicine, transportation (e.g. visiting private clinics and hospital 
admission) and accommodation for relatives during the course of their child being 
hospitalized, and work loss of relatives due to caregiving.    
5.2.3 Enterovirus detection and serotype determination 
A combination of PCR and sequencing were employed to identify enterovirus 
serotypes causing HFMD. Because of the focus of this chapter, EV-A71 positive 
samples were not subjected to genotype determination, otherwise the PCRs and 
sequencing procedure were carried out as previously described in Chapter 3 [109] 
and Appendix 1. 
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5.2.4 Components of economic costs and data analysis  
An overview about economic burden components of HFMD is presented in Figure 
5.1. The total illness costs consist of direct costs and productivity costs (Figure 
5.1). The former includes direct medical and non-medical costs. Direct medical 
costs consist of the costs associated with the goods and resources directly related 
to medical services over the course of illness (e.g. before hospital admission, 
during hospitalization and seven days after discharge), and direct non-medical 
costs consist of the costs associated non-medical resources (such as transportation, 
food and accommodation). The productivity costs (also known as indirect costs) 
include the costs attributed to work loss of relatives due to caregiving before 
hospital admission, during hospitalization and seven days after discharge. The 
estimation of productivity costs was based on the numbers of work-off days, 
collected during the face-to-face interview, and average salary for those with paid-
work or average minimum income for those with unpaid work [158,159]. I 
retrieved average salary and minimum income of Vietnamese people for the 
period of the study duration from [160,161]. The productivity loss of children 
(such as from missed school days) was not valued. 
The analysis took the societal perspective, which quantity all of the costs 
associated with an intervention/healthcare, regardless of whom they are incurred 
by. It was not possible to stratify the costs depending on if they were incurred by 
the health care provider or the patients themselves. No excess mortality was 
considered in the calculation of productivity costs.  
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I summarized all values of illness costs as means and 95% confident intervals 
(95%CI) in US dollars with an average conversion rate of 1 US$ equivalent to 
22,000 Vietnamese Dong for the duration of the study period (2016 – 2017) [162]. 
All statistical analyses were done using IBM SPSS Statistics for Window version 
23 (Armonk, NY: IBM Corp.) 
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Figure 5.1: Individual components of total costs attributed to HFMD 
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5.2.5 Estimation of total economic burden of HFMD at nationwide level 
during 2016–2017 
To estimate the economic burden of HFMD at nation-wide level in Vietnam 
during the study period, I first calculated the number HFMD outpatients seeking 
for medical treatment at CH1 during 2016–2017 using the formula:  
The number of outpatients = the number of outpatient visits⁄2 − α×the number of 
outpatient visits⁄2 
Where 2 is the average numbers of outpatient department visits per HFMD 
episode as per the medical practice in Vietnam [163]; α is the proportion of 
outpatients progressing to inpatients calculated based on the data collected from 
the present clinical study; and the number of outpatient visits were the data for 
2016–2017 period, and were retrieved from the database record of CH1.  
Using the numbers of hospitalized HFMD cases at CH1 during 2016–2017, which 
were retrieved from the hospital database record, and the number of estimated 
outpatients at CH1 obtained using the above formula, I calculated the ratio of 
inpatient and outpatients (β). With this obtained β value, I extrapolated the number 
of outpatients at nation-wide level during 2016–2017 by dividing the number of 
hospitalized cases across Vietnam by β. Finally, the total economic burden of 
HFMD in Vietnam is the sum of illness costs posed by inpatients and outpatients, 
which were calculated using the estimated illness costs for respective patient 
groups obtained in the present study and the estimated number of inpatients and 
outpatients across Vietnam.  
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5.2.6 Ethical statement 
The Institutional Review Board of CH1, CH2 and HTD, and the Oxford Tropical 
Research Ethics Committee (OxTREC) approved the study. Written informed 
consent was obtained from a parent or guardian of each enrolled patients. 
5.3 Results 
5.3.1 Baseline characteristics of the patients 
During April 2016–December 2017, a total of 466 patients were enrolled in the 
clinical study, including 427 inpatients and 39 outpatients. The baseline 
characteristics and clinical outcome are presented in Table 5.1. The majority 
(203/466, 43.6%) of the patients lived in Ho Chi Minh City, and only 25/466 
(5.4%) were transferred from other hospitals. 436 patients (93.6%) had between 2 
to 4 caregivers during the course of illness. The number of patients with severe 
HFMD (i.e. Grade 2B1 or above) accounted for 15.5%. Of 39 outpatients (Grade 
1), two were subsequently progressed to Grade 2A and were then admitted to the 
hospital without additional deterioration. These two patients were treated as 
inpatients in subsequent analyses. Compared with mild patients, patients with 
severe HFMD were admitted to the hospitals later (Table 5.1) and had a longer 
duration of hospitalization; median number of days (range): 2 (0–7) vs. 1 (0–7), 
P=0.009 and 5 (1–11) vs. 3 (1–31), P<0.001, respectively (Table 6.1). In terms of 
clinical outcome, 463 (99.4%) patients recovered without complication, while 
unfavourable outcomes were recorded in three, including pneumonia (n=1), 
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paralysis (n=1) and death (n=1). The fatal case had no enterovirus found in the 
collected swabs by the diagnostic work up of the present study. 
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Characteristics Total 
(n=466) 
Mild* 
(n=394) 
Severe
#
 
(n=72) 
Outpatients 
(n=37) 
Inpatients 
(n=429) 
P
1
 P
2
 
Sex ratio, male/female 271/195 226/168 45/27 16/21 255/174 0.42 0.055 
Median age in months (range)  17.5 (4–103) 17 (4–103) 19 (4–58) 22(7–85) 17(4–103) 0.29 0.11 
Transferred from other hospitals 25 (5.4%) 10 (2.5%) 15 (20.8%) 0 25 (5.8%) <0.001 0.25 
Geographic locations         
Ho Chi Minh City (n, %) 203 (43.6) 171 (43.4) 32 (44.4) 29(78.4) 174(40.6) 0.87 0.0001 
Other provinces (n, %) 263 (56.4) 223 (56.6) 40 (55.6) 8(21.6) 255(59.4) 
Median illness days before admission 
(range) 
1 (0–7) 1 (0–7) 2 (0–7) 1 (0-3) 1(0–7) 0.009 ND 
Median length of stay (range) 3 (1–31) 3 (1–31) 5 (1–11) NA 2(1–30) <0.001 NA 
Number of caregivers per child        
1 30 (6.4) 25 (6.3) 5 (6.9) 13 (35.1) 18 (4.2)  
0.85 
 
<0.001 2 374 (80.3) 316 (80.2) 58 (80.6) 23 (62.2) 348 (81.1) 
3 60 (12.9) 51 (12.9) 9 (12.5) 1 (2.7) 61 (14.2) 
4 2 (0.4) 2 (0.5) 0 0 2 (0.5) 
Occupation of caregivers (n, %)        
Paid  639 (66.1) 538 (65.7) 101(68.2) 34 (54.8) 601 (66.6)  
0.55 
 
0.06 Unpaid  328 (33.9) 281 (34.3) 47 (31.8) 28 (35.2) 302 (33.4) 
Median number of days off from work 
(range) 
12.5 (1.25–44) 12 (1.25–44) 15 (3.5–40) 8(1.25-15.5) 13 (2.5–44) <0.001 0.004 
Table 5.1: Baseline characteristics and etiology of patients enrolled in the study 
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Note to Table 5.1: *grade 1/2A, 
#
grade 2B1 or above; **pneumonia (n=1), and prolonged fever and diaphragm paralysis (n=1), 
$
the fatal case was unknown 
etiology; 

ND: not done (because of enrolment bias, see patient enrolment for more details); 
1
comparison between severe and mild cases; 
2
comparison between 
out and in patients; EVs: enteroviruses. 
 
 
Highest clinical grade (n, %)        
Grade 1  39 (8.3) 39 (8.3) NA 37 (100) 2 (0.5) NA NA 
Grade 2A  355 (76.2) 355 (76.2) NA 0 355 (82.8) NA NA 
Grade 2B1  24 (5.2) NA 24 (5.2) 0 24 (5.6) NA NA 
Grade 2B2  12 (2.6) NA 12 (2.6) 0 12 (2.8) NA NA 
Grade 3  36 (7.7) NA 36 (7.7) 0 36 (8.4) NA NA 
Outcome at discharge (n, %)        
Full recovery 463 (99.4) 392 (95.5) 71 (98.6) 37 (100) 426 (99.3)  
0.054 
 
0.88 Recovery with complication** 2 (0.4) 2(0.5) 0 0 2 (0.5) 
Death
$
 1 (0.2) 0 1 (1.4) 0 1 (0.2) 
Etiology (n, %)        
EV-A71 90 (19.3) 58 (4.7) 32 (44.4) 9 (24.3) 81 (18.9)  
 
<0.001 
 
 
0.079 
CV-A6 71 (15.2) 67 (17.0) 4 (5.6) 6 (16.2) 65 (15.2) 
CV-A10 43 (9.2) 40 (10.2) 3 (4.2) 1 (2.7) 42 (9.8) 
CV-A16 32 (6.9) 28 (7.1) 4 (5.6) 1 (2.7) 31 (7.2) 
Other EVs 109 (23.4) 98 (24.9) 11 (15.3) 14 (37.8) 95 (22.1) 
PCR negative 121 (26) 103 (26.1) 18 (25) 6 (16.2) 115 (26.8) 
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Table 5.2: Baseline characteristics of patients infected with different EV serotypes  
Characteristics EV-A71 
(n=90) 
CV-A6/10/16 
(n=146) 
Other EVs 
(n=109) 
P
1
 P
2
 
Sex ratio, male/female 54/36 94/52 63/46 0.50 0.75 
Median age in months (range) 21.5 (7–68) 16 (5–77) 19 (4–63) <0.001 0.10 
Transferred from other hospitals (n, %) 2 (2.2) 11 (7.5) 6 (5.5) 0.14 0.30 
Geographic locations      
Ho Chi Minh City (n, %) 43 (47.8) 66 (45.2) 52 (47.7) 0.7 0.99 
Other provinces (n, %) 47 (52.2) 80 (54.8) 57 (52.3) 
Median illness days before admission (range) 2 (0–7) 1 (0–5) 1 (0-6) <0.001 0.054 
Median days of hospitalization (range) 3 (1–10) 2 (1–30) 2 (1–9) 0.005 0.008 
Number of caregivers per child      
1 12 (13.3) 6 (4.1) 2 (1.8) 0.004 0.0001 
2 60 (66.7) 119 (81.5) 97 (89) 
3 18 (20) 21 (14.4) 9 (8.3) 
4 0 0 1 (0.9) 
Occupation of caregivers (n, %)      
Paid 121 (65.1) 197 (64) 160 (70.2) 0.81 0.27 
Unpaid 65 (34.9) 111 (36) 68 (29.8) 
Median number of days off from work (range) 14 (2-30) 12 (4.5–44) 11 (2.5–27) 0.057 0.004 
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Highest clinical grade (n, %)      
Grade 1 9 (10.0) 9 (6.2) 15 (13.8) <0.001 <0.001 
Grade 2A 49 (54.4) 126 (86.3) 83 (76.1) 
Grade 2B1 7 (7.8) 6 (4.1) 5 (4.6) 
Grade 2B2 6 (6.7) 1 (0.7) 3 (2.8) 
Grade 3 19 (21.1) 4 (2.7) 3 (2.8) 
Outcome at discharge (n, %)      
Full recovery 90 (100) 145 (99.3) 109 (100) 1 NA 
Recovery with complication 0 1 (0.7)** 0 
Death 0 0 0 
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5.3.2 Results of etiological investigations 
The results of enteroviral diagnostic are presented in the Table 5.1 & Table 5.2. 
Enteroviruses were identified in 74% of the 466 enrolled patients with EV-A71, 
CV-A6, CV-A10 and CV-A16 being the most common viruses identified, 
accounting for 90/466 (19.3%), 71/466 (17%), 43/466 (9.2%) and 32/466 (6.9%), 
respectively (i.e. 50.6% of total enrolled cases). While the detection rates of these 
common causes were similar among inpatients and outpatient groups, the 
detection rates were statistically different between hospitalised patients with 
severe and mild HFMD, with EV-A71 being more commonly detected in patients 
with severe clinical phenotypes (Table 5.2), supporting previous reports linking 
EV-A71 infection to severe disease [164]. Notably, EV-A71 PCR positive patients 
were older than those infected with CV-A6/10/16, and had a longer duration of 
hospitalization and later hospital admissions (Table 5.2).  
5.3.3 Illness costs attributed to HFMD: a general overview  
The detailed economic burden associated with HFMD for all enrolled patients and 
for different patient groups are presented in Table 5.3. Overall, there were 
considerable differences in direct medical costs between groups of patients with 
different clinical severities and patients infected with different pathogens (i.e. EV-
A71 vs. non-EV-A71). In contrast, the direct non-medical and productivity costs 
were relatively similar between patient groups. The mean total economic burden 
per case was estimated to be US$400.8 (95%CI: 353.8–448.9), of which the total 
direct costs accounted for 69.7% (mean: US$279.3, 95%CI: 235.3–328.9), while 
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direct medical costs accounted for 51.1% (mean: US$204.7, 95%CI: 162.1–
253.1).  
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Table 5.3: Economic costs associated with HFMD in Vietnam 
 
Note to Table 5.3:
 #
Data are presented as mean (95%CI); *grade 2b1 or above; **see Figure 1; EVs: enteroviruses; 
$
inpatients only; 
ND: not done; NA: non applicable; 

comparison
 
made for total economic costs 
Patient groups# Direct medical costs 
(US$) 
Direct non-medical costs 
(US$) 
Total direct costs (US$) Productivity costs 
(US$) 
Total economic costs 
(US$)** 
P values  
All patients (n=466) 204.7 (162.1–253.1) 74.6 (68.8–80.9) 279.3 (235.3–328.9) 121.5 (116.4–126.2) 400.8 (353.8–448.9) NA 
Geographic locations       
HCMC (n=203) 221.9 (145.5–300.0) 46.3 (41.7–50.8) 268.2 (190.1–346.7) 113.5 (106.7–120.4) 381.7 (302.9–464.5) 0.50 
Other provinces (n=263) 191.4 (134.9–254.6) 96.5 (88.0–105.6) 287.9 (230.7–351.6) 127.6 (121.1–134.4) 415.5 (355.8–480.9) 
In/outpatients       
Out patients (n=37) 16.8 (13.5 –19.5) 14.5 (8.2–22.3) 31.2 (24.9–38.4) 63.6 (54.1–73.9) 94.8 (81.7-108.7) <0.001 
Inpatients (n=429) 220.9 (173.3–271.4) 79.8 (73.5–86.7) 300.7 (250.7–351.2) 126.5 (121.8–131.6) 427.2 (376.8–478.6) 
Disease severities$       
Mild (n=357) 50.6 (41.7–63.5) 74.8 (69.7–80.0) 125.4 (113.9–139.9) 120.3 (115.5–125.7) 245.8 (231.9–261.3) <0.001 
Severe* (n=72) 1065.2 (883.5–1269.4) 104.6 (83.7–133.6) 1169.8 (986.1–1368.0) 157.0 (143.7–171.0) 1326. 7 (1144.6–1528.9) 
Grade 2B1 (n=24) 342.8 (142.3–578.5) 109.1 (71.9–152.8) 451.9 (241.2–702.5) 145.3 (123.3–167.2) 597.2 (396.3–839.8) ND 
Grade 2B2 (n=12) 795.2 (521.5–1100.7) 86.3 (66.9–104.0) 881.4 (609.1–1185.5) 163.3 (133.2–189.8) 1045.0 (772.6–1341.9) ND 
Grade 3 (n=36) 1,636.7 (1412.3–1,865.2) 107.7 (77.2–157.2) 1744.5 (1,539.7–1,965.4) 162.4 (140.7–183.7) 1861.0 (1,687.8–2,088.9) ND 
Pathogens       
EV-A71 (n=90) 502.2 (349.4–669.8) 74.8 (62.1–90.7) 577.0 (422.8–745.8) 128.9 (117.7–140.6) 706.0 (544.1–878.3) <0.001 
CV-A6/10/16 (n=146) 96.5 (53.3–150. 2) 72.6 (64.6–81.6) 169.1 (125.3–225.6) 118.1 (109.1–125.9) 287.1 (238.9–348.3) 
Other EVs (n=109) 118.2 (62.7–194.4) 70.2 (56.9–87.1) 188.4 (128.3–268.5) 113.1 (104.1–122.7) 301.5 (238.0–382.0) <0.001 
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5.3.4 Economic burden of HFMD by geographic locations, disease severity 
and pathogens 
In terms of geographic locations, albeit not statistically significant, the associated 
economic costs of patients coming from other provinces were slightly higher than 
that of patients living in HCMC (mean: US$415.5, 95%CI: 355.8–480.9 vs. mean: 
US$381.7, 95%CI: 302.9 –464.5), which was attributed to the higher direct non-
medical costs (such as travel costs) of patients coming from other provinces rather 
than HCMC (Table 5.3).  
As expected, patients with severe HFMD were associated with a significantly 
higher total illness costs compared to those with mild disease (including 
outpatients and inpatients with Grade 2A) (Table 5.3), of which the majority were 
attributed to direct medical costs. Additionally, of the severe patients (i.e. Grade 
2B1 or above), the higher clinical grades, the more illness costs were; estimated 
mean of total illness costs (95%CI): US$597.2 (396.3–839.8) for Grade 2B1, 
1045.0 (772.6–1341.9) for Grade 2B2 and 1861.0 (1,687.8–2,088.9) for Grade 3.  
In terms of enterovirus serotypes and associated costs, because EV-A71 was 
predominantly found in patients with severe clinical phenotypes, as a consequence 
the estimated mean illness costs attributed EV-A71 were higher than that of other 
HFMD causing enterovirus serotypes (including CV-A6, CV-A10 and CV-A16) 
(Table 5.3). 
5.3.5 Total economic burden of HFMD at nation-wide level in Vietnam 
during 2016–2017 
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During the study period, Vietnam recorded a total of 94,313 hospitalized HFMD 
cases (47,428 cases in 2016 and 46,885 case in 2017) [139]. Accordingly, the 
estimated number of outpatients in Vietnam during 2016–2017 is 532,397. This 
would be equivalent to a nation-wide total economic burden posed by HFMD 
cases presenting to hospitals in Vietnam of US$90,761,749 (95%CI: 79,033,973–
103,009,756) (Table 5.4). 
Table 5.4: Estimated total economic burden of HFMD cases presenting to 
hospitals in Vietnam during 2016–2017  
HFMD cases  Statistics 
Reported outpatient visits at CH1* 95,405 
Estimated number of outpatients at 
CH1** 
45,256 
Hospitalized cases at CH1* 8,017 
Hospitalized cases in Vietnam 94,313 
Estimated number of outpatients in 
Vietnam
#
 
532,397 
Illness costs in US$ Mean (95%CI) 
Outpatients  50,471,235 (43,496,835 – 57,871,554) 
Inpatients  40,290,514 (35,537,138 – 45,138,202) 
Total 90,761,749 (79,033,973 – 103,009,756) 
 
Note to Table 5.4: *derived from database record of CH1, **the proportion of outpatients 
progressing to inpatients (α): 2/39=0.05128; #the ratio of inpatient and outpatients 
(β):8,017/45,256=0.17715;  
5.4 Discussion 
Despite the public health threat of HFMD, scarce information about its economic 
burden is available to support policy makers in endemic countries in prioritizing 
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the resources for the development and implementation of intervention strategies, 
especially vaccines. Likewise, no data exists for the economic burden of HFMD in 
Vietnam. In this chapter, I describe the results of a prospective multi-hospital 
based study during 2016–2017, aiming at estimating the economic burden of 
HFMD in Vietnam, where HFMD has become a major clinical problem since 
2005, representing the first report about illness costs of HFMD in Vietnam. The 
results show that HFMD caused substantial economic burden in Vietnam, 
corresponding to estimated costs of US$90,761,749 (95%CI: 79,003,973–
103,009,756) for the period between 2016 and 2017, and that illness costs varied 
between enteroviruses and disease severities. EV-A71 caused the highest 
economic burden, especially if the disease was severe, and the higher costs were 
mostly attributed to the direct medical costs. In contrast to the fluctuations of the 
direct medical costs, the in-direct medical costs and productivity losses were 
similar across the clinical phenotype groups. Around 50% of the HFMD economic 
burden is out-of-pocket payments. This is a substantial burden at a national level, 
especially for a developing country like Vietnam. 
Although comparison of the illness costs between studies conducted in different 
countries has limitations due to the differences in study designs and 
social/economic statuses, the obtained results in this chapter are in agreement with 
previous reports including those from China and Taiwan [31,164,165]. A recent 
study from China reported the total costs for outpatients and inpatients with mild 
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and severe HFMD were US$196 (95%CI: 75–318), US$990 (95%CI: 431–1549) 
and US$3084 (95%CI: 813–5354). While the data from China was retrospectively 
obtained through telephone interview of the participants, and may therefore not 
accurately estimate the disease burden, the higher estimated costs for respective 
disease groups in China may be due to the difference in social economic statuses 
between Vietnam and China [166]. Additionally, in line with a recent report from 
Taiwan [31], our results showed that EV-A71 infection resulted in higher illness 
costs than other HFMD causing enterovirus serotypes did, attributable to the 
predominance of EV-A71 found among patients with severe HFMD. The 
productivity costs were similar between groups of patients infected with different 
enterovirus serotypes.  
The obtained results of etiological investigation showed, although HFMD is 
diverse in etiology, EV-A71 was predominantly found in patients presenting with 
Grade 2B1 or above (i.e. severe HFMD). As such, my findings are consistent with 
previous etiological studies in the region [135,167]. Of note, existing serological 
data obtained from vaccine trials and in vitro experiments suggest cross-
neutralization against heterogeneous serotypes of HFMD causing enteroviruses are 
absent and/or insufficient to provide long-term protection [113,148,157]. 
Collectively, my and others data indicate that multivalent vaccines are needed to 
control HFMD [157]. However, while the development of such multivalent 
vaccines might be highly challenging because of the unprecedented emergence of 
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HFMD causing viruses [76], effective EV-A71 vaccine(s) are urgently needed as 
such interventions would substantially reduce the major (~50%) burden caused by 
severe HFMD.  
The strengths of my study include that it was prospectively conducted at major 
hospitals in Ho Chi Minh City, Vietnam, with a catchment population of over 40 
million and that the data on illness costs was comprehensively captured from both 
in- and outpatients for the periods before hospital admission, during 
hospitalization and one week after discharge. Few economic burden studies in this 
area have reported such level of details [168].  
My study has some limitations. First, I only based the economic burden 
estimations at nationwide level on cases presenting to hospitals for medical 
treatments, but did not take into account those seeking for medical treatments at 
private clinics or being managed at home by parents. Therefore, I may have under-
estimated the economic burden of HFMD in Vietnam. Second, I extrapolated the 
total costs using our estimated illness costs data obtained from major hospitals in 
Ho Chi Minh City, an urban setting, while around 50% of HFMD patients are 
managed at provincial hospitals, which may result in lower hospital costs. I may 
therefore have overestimated the economic burden of HFMD at nationwide level.  
Third, despite our holistic approach, it is not always straightforward to accurately 
value productivity losses, which is subjected to variations in income of the 
population, particularly those with unpaid work. Collectively, the results, 
 138 
 
especially the data on economic burden at the nationwide level, should be 
interpreted with caution.  
5.5 Conclusion 
To summarize, for the first time, I show that HFMD causes substantial annually 
economic burden in Vietnam. An effective EV-A71 vaccine could substantially 
reduce the majority of severe cases, thereby significantly reducing the illness costs 
from severe disease. My results will be helpful for policy makers in Vietnam in 
prioritizing resources for the development and implementation of intervention 
strategies, including vaccines, to reduce the burden of HFMD. 
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Chapter 6 
General discussion and future directions 
 
Since 1997, HFMD has become a major public health concern in Asia and beyond, 
affecting mostly children under 5 years old. The disease poses a substantial threat 
to society, especially when outbreaks occur. It is caused by a group of 
enteroviruses, especially EV-A71, CV-A6, CV-A10 and CV-A16. Although the 
vast majority of cases are mild and self-limiting, a small proportion of patients 
may progress to severe diseases, which can result in long-term sequelae or fatality. 
There are currently no clinically proven effective antiviral. EV-A71 vaccines have 
been used in selected population in China [169], while phase three trials of EV-
A71 vaccines have also been conducted in Vietnam [111]. Despite this progress, 
there remain significant gaps in knowledge about important aspects of this 
emerging infection, especially in settings like Vietnam where HFMD has 
periodically overwhelmed the healthcare systems since 2005. As such, I set out to 
conduct a comprehensive research program aiming at addressing unanswered 
questions about epidemiology, disease pathophysiology, and economic burden of 
HFMD in Vietnam, which I will discuss herein. 
My specific hypotheses were 
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1. The ongoing epidemic of HFMD in southern Vietnam, especially in Ho 
Chi Minh City, is complex and is driven the emergence of pathogens. 
2. HRV indices are different between HFMD patients infected with 
different viruses and/or presenting with different clinical severities. 
3. HFMD causes a substantial economic burden in Vietnam that needs to 
be assessed to inform decisions about vaccination 
6.1 Epidemiology 
To investigate the patterns of HFMD and the factors driving this, using hospital 
data, I have described the patterns of spread of HFMD in Ho Chi Minh City over 
an 11-year period (2005 – 2015). I identified that the spreading patterns of HFMD 
in HCMC were as follows: starting in the north-west of HCMC, HFMD moved 
south-east and then returned to the western part of the city. Additionally, over this 
11 year period, there were more than 56,000 hospitalized cases due to HFMD in 
HCMC. My data also consistently showed that the affected patients were young 
children. Because the majority of families in HCMC are nuclear families, meaning 
that parents may have had to take time off from work to care for their children, my 
data thus emphasize that HFMD has posed a significant burden on the society as a 
whole in Vietnam. These findings have stimulated me to conduct prospective 
studies to gain further insights into the epidemiology, pathophysiology and 
economic burden of this emerging infection in Vietnam.  
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One of the main findings of my prospective hospital based study was that among 
19 enterovirus serotypes detected in 80% of ~1200 patients with HFMD; EV-A71, 
CV-A6, CV-A10 and CV-A16 were the most common pathogens circulating and 
causing HFMD in Vietnam during 2015 – 2018, supporting findings from the 
region [169,170]. Moreover, together with data synthesized during 2013 – 2015 as 
part of the ongoing HFMD research program in the collaboration between 
OUCRU, CH1, CH2 and HTD, for the first time, long-term etiological data of 
HFMD in southern Vietnam were generated. Fascinatingly, unlike observational 
data from Malaysia, Taiwan and Singapore, where EV-A71 infection exhibited a 
2-3 yearly cyclic pattern [19,171], in Vietnam EV-A71 activity has generally been 
documented annually, and EV-A71 cases were more often observed in the second 
half of the year. In contrast, CV-A6/10/16 were more frequently detected in the 
first half of the year. In other words, several serotypes of enteroviruses were 
responsible for the HFMD burden in Vietnam. Therefore, although a monovalent 
vaccine could significantly reduce the burden of (severe) HFMD, multivalent 
vaccines should be developed in order to control this emerging infection.  
Another key finding was the emergence of CV-A6, and the relative absence of 
EV-A71 in 2017 and the first half of 2018, potentially causing an EV-A71 
immune window that allowed the large outbreak occurring in southern provinces 
of Vietnam in late 2018 [135]. Using  data obtained from the clinical study 
conducted as part of my PhD research, I was the first to identify and report the 
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unprecedented upward trend of severe HFMD cases and the reemergence of 
subgenogroup C4 in Vietnam in 2018 [135]. This put my hospital (CH1) in a very 
good position to handle last year’s HFMD outbreak.  
Despite the emergence of coxsackieviruses, especially CV-A6, EV-A71 remains 
the major cause of severe HFMD in Vietnam. Additionally, I showed for the first 
time that compared to subgenogroup B5, C4 caused more severe disease and the 
dominance of C4 coincided with large, severe HFMD outbreaks in Vietnam 
(2011-12 and 2018). As such, I propose that active hospital-based surveillance 
should be continuously conducted so as to promptly detect subgenogroups with 
potential of causing severe outbreaks and the sudden increase of cases with severe 
HFMD. This would enable us to inform local health authorities and clinicians 
about potential  HFMD outbreaks in a timely manner, allowing appropriate public 
health staff preparations.  For example enhancing practice of hand washing, 
training staff how to recognize a suspected case of HFMD in kindergartens, re-
training health staff on the key signs/symptoms associated with severe HFMD and 
preparing sufficient drugs for treatment of critically cases (e.g intravenous 
immunoglobulin, milrinon, mechanic ventilators and hemofiltration machines).      
6.2 Heart rate variability 
In terms of HFMD pathophysiology, my thesis focused on describing the HRV 
indices in children with differing severities and aetiologies of HFMD in order to 
address my second hypothesis described above. HRV has been mentioned as a 
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non-invasive marker for detecting ANS imbalance, which may be present in 
severe HFMD. Differing from [104], the present study used E-patches to record 
the ECG signal for hours instead of just 5 minutes from specific monitors so that 
we could have more data to produce time series of HRV indices for further 
analysis.  
One of the striking findings was that there was association between EV-A71 
infection and ANS imbalance including both elevation of sympathetic activity and 
reduction of parasympathetic activity among all levels of severity of illness. This 
finding improves and supports our understanding of the mechanism of severe 
HFMD. MRI studies have indicated that EV-A71 invades the CNS, causing 
brainstem encephalitis and especially damages medulla oblongata, the region that 
modulates ANS balance [5,19,172]. In severe disease ANS dysfunction is thought 
to be a major cause of cardiorespiratory instability and death. The  finding from 
this study is consistent with several studies [170,171] which have reported that 
children with HFMD caused by EV-A71 were more likely to develop severe 
disease with ANS dysfunction compared to those infected by other EV serotypes.   
Another finding was that there were significant differences in HRV indices 
reflecting activation of both sympathetic and parasympathetic arm of ANS 
between different groups of disease severity. This suggests that the HRV indices 
(RMSSD, HF, LF, HFnu, LFnu, LF/HF ratio, SD1, SD2, SD1nu, SD2nu, pLF1, 
pLF2, pHF1, pHF2, IMAI1 and IMAI2) may have potential applications in 
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discriminating severity of the disease. Moreover, as aforementioned, these HRV 
indices were produced from ECG signal recorded by wearable devices (E-patches) 
for up to 24 hours. These data could be further analyzed using different methods  
in future. For example, from time series of these HRV indices an algorithm could 
be built and extracted, using machine learning, potentially developing a 
classification method for HFMD based on an ECG signal. The algorithm could be 
incorporated into an app which could be created and installed to smart phones of 
nurses and doctors for monitoring patients in their daily work. Every time, the 
selected HRV indices are over their threshold a massage or alarm noise will be 
sent to medical staff’s phones.   
6.3 Economic burden  
My final hypothesis was that HFMD causes a major economic burden in Vietnam. 
It is widely acknowledged in the international literature that HFMD has become a 
major public health issue in Asia and other parts of the world because of its health-
care associated burden, and my study provides evidence of its economic burden. 
Vaccination has been considered as a possible solution to control this emerging 
infection and three inactivated EV-A71 vaccines have been used in China while 
two others are being evaluated in Vietnam. Therefore, estimating the economic 
burden of HFMD is very useful for health policy makers in Vietnam in prioritizing 
to the introduction of vaccine. From the societal perspective, my thesis aimed to 
estimate the economic costs of HFMD in children presenting to outpatient clinics 
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and inpatient wards of the three major hospitals in Ho Chi Minh City through a 
prospective observational study. The economic costs of HFMD at national wide 
level were then also extrapolated.   
My PhD research showed that the mean total costs of a HFMD case presenting in 
outpatient and inpatient ward was roughly US$95 and US$427, respectively. More 
specifically, direct costs, direct non-medical costs, indirect costs accounted for 
17.7% (16.8/94.8), 15.3% (14.5/94.8) and 67% (63.6/94.8) of the mean total cost 
of outpatient group, respectively whereas the corresponding figures in inpatient 
group were 51.7% (220.9/427.2), 18.7% (79.8/427.2) and 29.6% (126.5/427.2). 
Among inpatients, patients with severe clinical phenotypes posed higher economic 
costs than those with mild diseases did. Likewise, because EV-A71 was the major 
cause of severe HFMD, economic costs attributed to EV-A71 infections were 
higher than that of other pathogens (e.g. CV-A6, CV-10 and CV-10). Overall, the 
estimated total economic costs of outpatients and inpatients at national level in 
Vietnam were around $50.47 million and $40.29 million, respectively for the 
period between 2016 and 2017 (Table 5.4). In summary, for the first time I 
quantified the substantial economic burden of HFMD in Vietnam during 2016 and 
2017. Together with the obtained virological data, the results showed that although 
EV-A71 vaccines could significantly reduce the economic burden of HFMD, 
multivalent vaccines should be developed to control the ongoing HFMD epidemic.       
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6.4 Perspective and future directions 
Considered as part of the global field of HFMD research, my thesis has 
contributed significantly in many areas. Despite recent advances, several 
important gaps in knowledge about this emerging infection remain to be unraveled 
and should, from my perspective, be addressed in future studies. In particular, it is 
unknown why HFMD pathogens such as EV-A71, CV-A6, CV-A10 and CV-A16, 
which were isolated over six decades ago, have explosively emerged since 1997. 
Additionally, although the epidemic of HFMD, especially severe outbreaks, was 
originally confined to the Asia-Pacific region, over the last years, there have been 
numerous HFMD outbreaks reported elsewhere in Europe and most recently in the 
United States in 2018 [8,173]. Collectively, I hypothesize that population 
immunity and/or host genetics might play a role. As such, comprehensive 
serosurveillance combined with modeling approach assessing the association 
between population immunity and disease emergence, and studies focusing on 
identifying potential genetic makers associated with severe HFMD are of 
particular interest from both clinical management and public health perspectives. 
Notably, previous studies from China have shown that HLA-A33 is associated 
with EV-A71 susceptibility [5,16,174].  
As a clinician, I am also particularly interested in identifying how to best diagnose 
and manage patients with severe HFMD, especially those at risk of deterioration.  
Findings on HRV in Chapter 4 are obviously just the beginning of a new story, 
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and have opened up a new opportunity to look into the utility potential of portable 
devices like E-patches and the information they offer, which can potentially be 
translated into patient management. Indeed, work is currently ongoing with 
collaborators in Oxford to develop machine learning based approaches that can 
accurately predict disease progression and classify HFMD according to disease 
severity.  
Although it is highly challenging to carry out, the clinical benefit of intravenous 
immunoglobulin should be tested in the future. Likewise, because my PhD 
research has pointed out that there are currently around 20 enterovirus serotypes 
responsible for the ongoing HFMD epidemic in Vietnam, assessing the potential 
impact of EV-A71 monovalent vaccine on the epidemic dynamic of HFMD as a 
whole are essential to inform future directions on the development and 
implementation of interventions, especially EV-A71 vaccine. Last but not least, I 
believe that in relation to vaccine development and implementation, my data on 
economic burden have offered valuable information, which can serve as the basis 
for studies aiming at estimating the benefit that EV-A71 vaccine may offer, which 
should also be one of the focuses of a future HFMD research program.   
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Appendices 
Appendix 1: Laboratory procedures used for the detection and 
serotype/genogroup determination of enteroviruses  
 
Viral RNA extraction 
 
Viral RNA was extracted using QIAamp
®
 Viral RNA Mini Kits (QIAgen GmbH, 
Hilden, Germany) performed according to the manufacturer’s instruction and as 
following: 
1. Pipette 560 µl of buffer AVL containing carrier RNA into RNA free 1.5 ml 
microcentrifuge tube. 
2. Add 140 µl of throat/rectal swabs in viral transport medium to the tube.  
3. Add 20 µl of EAV (equine arteritis virus) to the mixture. 
4. Incubate at room temperature for 10 minutes then spin the tube for a few 
seconds to remove drops from the lid. 
5. Add 560 µl of absolute ethanol to the mixture, mix by pulse vortexting for 
15 seconds, and centrifuge briefly for a few seconds to remove drops. 
6. Careful transfer 600 µl of the lysate to QIAamp spin column. 
7. Spin at 13,200 rpm for 1 minute. 
8. Place the column onto a 2ml clean collection tube. Transfer the rest of 
lysate to the column. 
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9. Add 500 µl of buffer AW1 (provided in the kit). Centrifuge at 13,200 rpm 
for 1 minute.  
10. Place the QIAamp spin column in a new 2ml collection tube. 
11. Add 500 µl of buffer AW2 (provided in the kit). Centrifuge at 13,200 rpm 
for 3 minutes. 
12. Place the QIAamp spin column into a new 1.5ml collection tube and 
centrifuge for 1 minute to get rid of all AW2 buffer. 
13. Place the QIAamp spin column into an RNAse free 1.5 microcentrifuge 
tube. Carefully load 50 µl of buffer AVE (provided in the kit).  
14. Incubate at room temperature for 1 minute. Centrifuge at 14,000 rpm for 1 
minute. 
15. Load another 50 µl of buffer AVE to the column. Centrifuge at 13,200 rpm 
for 1 minute 
16. Transfer the eluted RNA (100 µl in total) into a clean 1.5ml Eppendorf tube 
and store at -80
o
C until analysis. 
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Multiplex real time PCR for simultaneous detection of enterovirus and 
enterovirus A71 
 
The detection of enterovirus and enterovirus A71 associated with hand, foot and 
mouth disease, was performed by real-time RT-PCR using SuperScript® III 
Platinum® One-Step qRT-PCR Kit (Invitrogen) and in the LightCycler480 (Roche 
diagnostics). The real-time RT-PCR reaction was carried-out in total volume of 25 
µl containing 12.5 µl of reaction mix (included in the kit), 1 µl of enzyme 
(included in the kit), 1 µl of each primer pair and 1 µl of each probe 
(Supplementary Table 1) [109], and 5 µl of viral RNA.  
The thermal cycling condition: 1 cycle at 60
o
C for 3 minutes, 53
o
C for 15 minutes 
and 95
o
C for 2 minutes, followed by 45 cycles at 95
o
C for 15 seconds, 53
o
C for 1 
minute with fluorophore reading, and 72
o
C for 15 seconds, and final extension at 
72
o
C for 10 seconds. 
Valid result interpretation when negative controls were negative and internal and 
positive controls were positive with Cp values within expected ranges (32-35).   
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Supplementary Table 1: List of primers and probes used for the multiplex real time RT-PCR 
[109]  
Name Sequence (5’3’) 
Working 
concentrat
ion (µM) 
Note 
EAVF primer CAT CTC TTG CTT TGC TCC TTA G 10 Internal 
control EAVR primer AGC CGC ACC TTC ACA TTG 10 
EAV-probe 
FAM-5’-CGCTGTCAGAACAACATTATTGCCCAC-
3’-BHQ1 
2.5 
ENT-F  5’-CCCTGAATGCGGCTAAT-3’ 10 Enterovirus  
ENT-R  5’- ATTGTCACCATAAGCAGCC-3’ 10 
ENTr-probe Cy5-ACCCAAAGTAGTCGGTTCCG -BHQ3 5 
EV71-634F3 GGAGAACACAARCARGARAAAGA 10 Enterovirus 
A71  EV71-743R3 ACYAAAGGGTACTTGGAYTTBGA 10 
EV71-probe Cyan500-TGATGGGCACDTTCTCRGTGCG-BHQ1 1 
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Enterovirus serotype determination  
 
Enterovirus serotype determination was carried out using a nested RT-PCR 
targeted at VP1 coding region.  
1. First round RT-PCR 
First round RT-PCR was performed using the SuperSript OneStep RT-PCR 
Platinum Taq (Invitrogen) in an Eppendorf PCR machine (Cat. 5333). The 
reaction was carried-out in a total volume of 20 µl containing 10 µl of 2X reaction 
mix (included in the kit), 1 µl of a 4 primer (AN32, AN33, AN34 and AN34; 
Supplementary Table 2) mixture (10 µM each), 0.5 µl enzyme (provided in the 
kit), 5 µl of viral RNA (extracted by QIAamp
®
 kit) and 3.5 µl of water.  
The thermo cylcing condition: one cycle at 55
o
C for 3 minutes, 22
o
C for 10 
minutes, and 42
o
C for 30 minutes. Then amplification was performed in the same 
PCR machine at the following conditions: 95
o
C for 1 minute followed by 40 
cycles of 94
o
C for 30 seconds, 42
o
C for 30 seconds and 60
o
C for 1 minute, and 
final extension at 72
o
C for 7 minutes.     
2. Second round PCR 
The second round PCR was performed using the Platinum PCR Super mix 
(Invitrogen) and each reaction contains 23 µl of the Platinum Super mix (included 
in the kit), 0.5 µl of each of the AN89 and AN88 primers (Supplementary Table 
2), and 1 µl of the first round RT-PCR product in total volume of 25 µl. The 
thermocyling condition was as following: 95
o
C for 1 minute followed by 40 cycles 
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of 94
o
C for 20 seconds, 55
o
C for 20 seconds, and 72
o
C for 10 seconds, and final 
extension at 72
o
C for 7 minutes. PCR products were then analysed in 2% agarogel 
and positive samples (PCR band at the expected size ~370bp) were purified using 
ethanol as following: 
a. To each tube of PCR product, add 2 µl of Sodium Acetate 3M.  
b. Add 60 µl of 95% cold ethanol to the tube and then transfer the mixture to 
1.5ml Eppendorf.  
c. Spin at stop speed (13,000 rpm) at 4oC for 10 minutes.  
d. Discard the aqueous phase and add 300 µl of 70% cold ethanol.  
e. Spin at stop speed for 5 minutes and discard the aqueous phase.  
f. Repeat the washing with 70% cold ethanol one more time.  
g. Air dry the pellet for 15 minutes and resolve the pellet in 25 µl of molecular 
grade water 
h. Store the purified PCR product at 20oC until use 
3. VP1 sequencing 
Sequencing was performed using BigDye Terminator Cycle Sequencing Kit (ABI, 
Cat. 4336917) in the 3130XL ABI sequencer platform. Each sequencing reaction 
contained 1 µl sequencing mix (included in the kit), 2 µl buffer (included in the 
kit), 11 µl water, 1 µl primer (AN232 or AN233; Supplementary Table 2), and 5 
µl purified DNA. The reaction was performed at 95
o
C for 1 minute, followed by 
 154 
 
30 cycles at 94
o
C for 20 seconds, 60
o
C for 2 minutes and finally hold at 10
o
C until 
ending. Products were purified with cold ethanol as following: 
a. To each tube of dye termination product, add 4 µl of STOP solution 
(containing 2 volume of EDTA, 2 volume of Sodium Acetate, and 1 
volume of Glycogen).  
b. Add 60 µl of 95% cold ethanol and then transfer the mixture to 1.5ml 
Eppendorf tube.  
c. Spin at stop speed (13,000 rpm) at 4oC for 15 minutes.  
d. Discard the aqueous phase and add 300 µl of 70% cold ethanol.  
e. Spin at stop speed for 5 minutes and discard the aqueous phase.  
f. Repeat the washing with 70% cold ethanol one more time.  
g. Dry the pellet in a vacuum dryer for 25 minutes. Then elute the pellet in 25 
µl of HiDi solution (included in the kit).  
h. The DNA was then transferred to a 96 ABI sequencing plate and sequenced 
in the ABI 3130XL sequencer using standard condition. 
4. Serotype determination 
Viral sequence data was assembled and edited using ContigExpress software, a 
component of the Vector NTI version 7.0 (Thermo Fisher Scientific). Viral 
sequence was then subjected to an online enterovirus genotyping tool available at 
https://www.rivm.nl/mpf/typingtool/enterovirus/ for serotype determination. 
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Supplementary Table 2: Primer sequences and working concentration [136] 
Name Sequence (5’3’) Application Working 
concentrati
on (µM) 
AN32 GTYTGCCA 1
st
 round RT-PCR 
10 µM of 
each  
AN33 GAYTGCCA 1
st
 round RT-PCR 
AN34 CCRTCRTA 1
st
 round RT-PCR 
AN35 RCTYTGCCA 1
st
 round RT-PCR 
AN89 CCAGCACTGACAGCAGYNGARAYN
GG 
2
nd
 round PCR (forward) 
10 
AN88 TACTGGACCACCTGGNGGNAYRWA
CAT 
2
nd
 round PCR (reverse) 
10 
AN232 CCAGCACTGACAGCA Sequencing 10 
AN233 TACTGGACCACCTGG Sequencing  10 
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Enterovirus A71 subgenogroup determination 
  
Enterovirus A71 PCR positive samples were sequenced to determine 
subgenogroup. The PCR condition (including the thermo cycling program) and the 
primers used are listed as below:  
RT-PCR  
Component  Voume per reaction 
2X buffer 12.5 ul 
EV71-VP1-3F (10uM) 1 ul 
EV71-VP1-703R (10uM) 1 ul 
Superscript III one-step RT PCR 0.5 ul 
Viral RNA 5ul 
Water 5 ul 
 
RT-PCR conditions: 
50
o
C for 30 minutes, 95
 o
C for 2 minutes, and followed by 45 cycles of 94
 o
C for 
20 seconds, 50
 o
C for 30 seconds, and 72
 o
C for 1 minute, and final extension step 
at 72
 o
C for 7 minutes. 
Supplementary Table 3: Primers sequences used for EV-A71 subgenogroup 
determination [40] 
 
EV71 VP1 
sequencing 
EV71-VP1-3F AGAYAGGGTGGCRGATGT 
701 bp EV71-VP1-
703R 
CTGAGAACGTGCCCATCA 
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Sequencing of the obtained PCR amplicon was carried out as described in the 
aforementioned VP1 procedure for serotype determination of enteroviruses using 
EV-A71 PCR primers. 
Appendix 2: Publication from chapter three 
Appendix 3: Publication from chapter five 
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